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INTRODUCTION 
 
Portal Hypertension is the most common and lethal complication of chronic 
liver diseases. It is responsible for the development of gastroesophageal varices, 
variceal hemorrhage, ascites, renal dysfunction, portosystemic encephalopathy, 
hypersplenism and hepatopulmonary syndrome. 
 
Portal hypertension commonly accompanies liver cirrhosis.  The development 
of esophageal varices (EV) is one of the major complications of portal 
hypertension.1   The prevalence of EV in patients with liver cirrhosis ranges 
from 60% to 80%. 2,3  Numerous evidences suggest that varices develop and 
enlarge with time. Christensen and colleagues showed that the cumulative 
incidence of varices in patients with cirrhosis increased from 12% to 90% over 
12 years.4  In a study, Cales and Pascal et al. showed 20% of patients who did 
not have varices developed new varices and 42% of patients with small varices 
showed definite enlargement.5  
 
The risk of bleeding from these varices is associated with the severity of the 
liver disease and the size of varices, which are the most important predictors of 
bleeding.6,7  It is estimated that approximately 60%–80% of patients with 
2 
 
cirrhosis develop esophageal varices during their life at a rate of 8% per year, 
and the progression from small to large varices occurs in 5%–10% of patients 
after the first year.8-11 
 
Portal hypertension related upper GI bleeding accounts for 15-20% of all upper 
GI bleeding cases in Western population12 and around 45% cases in Indian 
population.13  Large EVs (LEVs) are more likely to bleed than small EVs 
(SEVs)14 due to high variceal wall tension.15 Among 60% of cirrhotic patients 
who develop gastroesophageal varices, 50% will experience an episode of 
variceal hemorrhage within 2 years of the diagnosis of the varices.16,17 Majority 
of initial bleeds occurring with 1 year from the time of detection of varices.6, 18 
Up to one-third to half of the patients with advanced liver disease and large 
varices die after the first attack of variceal bleeding.19 
 
The mortality rate from first episode of bleeding is 40%.20   Mortality from each 
rebleeding episode is 20-30%. The reported overall mortality from variceal 
bleeding ranges from 17% to 57%. 2, 3 Introduction of prophylactic antibiotics 
and pharmacotherapy have shown to reduce the mortality.2, 3, 21 
 
The American Association for the Study of Liver Disease and the Baveno V 
Consensus Conference on portal hypertension recommended that all cirrhotic 
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patients should be screened for the presence of EV when liver cirrhosis is 
diagnosed.22, 23   Other authors have suggested repeating endoscopy at 2–3 year 
intervals in patients without varices and at 1–2 year intervals in patients with 
small varices so as to evaluate the development or progression of varices.9, 24  
 
Upper gastrointestinal  endoscopy, which is the most common and accurate 
procedure for evaluation of varices, is at times inconvenient for patients.25,26  It 
also bears a small risk of complications like esophageal perforation, aspiration 
of gastric contents and bacteremia.27,28  Moreover, sedation with 
benzodiazepines usually used for this procedure can significantly exaggerate 
hepatic encephalopathy.29 
 
Investigators have attempted to identify characteristics that ‘noninvasively’ 
predict the presence of varices. These studies have shown that biochemical, 
clinical, and ultrasonographic parameters alone or together have good predictive 
power for noninvasively assessing the presence of EV.30-43  Overall, the most 
common result of these studies was that parameters such as splenomegaly, 
thrombocytopenia, Childs score, ascites, portal flow patterns, and platelet 
count—spleen diameter ratio were predictors of the presence of EV. 
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Doppler ultrasonography can be regarded as an attractive and non-invasive 
alternative method and may provide useful functional information. Many 
investigations reported correlations between different hepatic vasculature 
Doppler indices and the severity of portal hypertension and the resultant 
esophageal varices.20, 35, 44-50 
 
Our study aimed to determine what Doppler indices of hepatic vessels can be 
used to predict the presence of esophageal varices and to evaluate the severity of 
esophageal varices.  
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AIM OF THE STUDY 
 
 
1. To evaluate portal hypertension parameters in liver cirrhosis by using 
Doppler ultrasound. 
 
2. To evaluate other non-invasive parameters in predicting esophageal 
varices. 
 
 
3. To correlate portal hypertension parameters in predicting Esophageal 
varices and upper GI bleed from esophageal varices. 
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REVIEW OF LITERATURE 
 
Portal hypertension (PHT) is defined by a pathologic increase in portal pressure 
above normal range of 6-10 mm or the pressure gradient between the portal vein 
and inferior vena cava (the portal pressure gradient [PPG]) is increased above 
the upper normal limit of 5 mm Hg.51-53 
 
Portal hypertension becomes clinically significant when the PPG increases 
above the threshold value of 10 mm Hg (e.g., formation of varices) or 12 mm 
Hg (e.g., variceal bleeding, ascites). PPG values between 6 and 10 mm Hg 
represent subclinical portal hypertension.51 
 
PPG is determined by the product of blood flow and vascular resistance within 
the portal venous system. The importance of portal hypertension is defined by 
the frequency and severity of complications: Massive upper gastrointestinal 
bleeding from ruptured gastroesophageal varices and portal hypertensive 
gastropathy (PHG), ascites, renal dysfunction, hepatic encephalopathy, arterial 
hypoxemia, disorders in the metabolism of drugs or endogenous substances that 
are normally eliminated by the liver, bacteremia, and hypersplenism.54  These 
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complications are major causes of death and the main indications for liver 
transplantation in patients with cirrhosis. 
 
Anatomical features of portal venous system:  
 
The name “portal vein” derives from the notion that it is the gate into which the 
splanchnic circulatory system is connected to the liver (porta = gate). This 
venous system originates in the capillaries of the intestine and terminates in 
the hepatic sinusoids.  
 
The portal vein is 6 to 8 cm long, formed by the union of the superior 
mesenteric vein and the splenic vein at the level of the second lumbar vertebra, 
just behind the neck of the pancreas which drains the stomach, the large and 
small intestine, the pancreas, and the spleen. The left gastric (coronary) vein 
joins the portal vein at its origin 50% of the time, and it joins the splenic instead 
of the portal vein in the other 50% of subjects. 
 
The segment of the portal vein after the last afferent branch runs in the 
hepatoduodenal ligaments (the free edge of the lesser omentum) in a plane 
dorsal to the bile duct and the hepatic artery. This segment extends for approx 
6–8 cm before entering the liver and it is 1–1.2 cm in diameter. The portal trunk 
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divides into two lobar veins before entering the portal fissure. The right lobar 
branch, short and thick, then receives the cystic vein. The left lobar vein is 
longer than the right and consists of a transverse and an umbilical part. Then the 
segmental branches of the portal vein split dichotomously into equal sized 
branches, constituting a tree of conducting vessels that terminate in venules. 
 
The recanalized umbilical or paraumbilical veins arise from the umbilical 
portion of the left portal vein and pass through the round ligament to the 
anterior abdominal wall, where they may become evident, in the presence of 
portal hypertension, in the umbilical varices. 
 
The portal vein is not provided with valves, so the pressure is transmitted freely 
back to the afferent branches. The portal vein pressure normally ranges between 
5 and 10 mmHg (depending on the method of measurement). Normal fasting 
hepatic blood flow is approx 1500 ml/min. About two-thirds of the total hepatic 
blood flow and about one-half of the oxygen consumption are supplied by the 
portal vein, whereas the remainder is supplied by the hepatic artery. This dual 
hepatic blood supply makes the liver rather resistant to hypoxia. 
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Portal Collateral Circulation: 
 
The portal system has numerous collaterals that interconnect with the systemic 
circulation. When portal pressure rises above 10 mmHg potential portosystemic 
collaterals may develop. The most important sites for the development of 
portosystemic collateral vessels are: 
 (1) esophageal submucosal veins, supplied by the left gastric vein and draining 
into the superior vena cava through the azygos vein; (2) paraumbilical veins, 
although normally non-functional, can serve as an anastomosis between the 
umbilical part of the left portal vein and the epigastric veins of the anterior 
abdominal wall that drain into the superior or inferior vena cava, and in special 
circumstances may form caput medusa at the umbilicus (Cruveilhier–
Baumgarten syndrome); (3) rectal submucosal veins, supplied by the inferior 
mesenteric vein through the superior rectal vein and draining into the internal 
iliac veins through the middle rectal vein;  (4) splenorenal shunts, in this case 
venous blood may be carried to left renal vein, either directly or by way of the 
diaphragmatic, pancreatic, or gastric veins; (5) short gastric veins communicate 
with the esophageal plexus; (6) within the cirrhotic liver, there is significant 
collateral flow in small veins that connect branches of the portal and hepatic 
veins. 
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The Gastroesophageal Junction: 
 
Clinically, the most significant collaterals are the intrinsic veins of the 
gastroesophageal junction, which are located close to the mocusal surface. They 
are the collaterals most likely to bleed when dilated because of increased blood 
flow. According to Vianna et al.55 There are four distinct zones of esophageal 
venous drainage (from distal to proximal): (1) the gastric zone, which extends 
for 2–3 cm just below the gastroesophageal junction. Veins from this zone drain 
into the short gastric and left gastric veins. (2) The palisade zone extends 2–3 
cm superiorly from the gastric zone into the lower esophagus and represent the 
watershed between the portal and systemic circulation. (3) The perforating or 
transitional zone extends approx 2 cm above the palisade zone. Characteristic 
features of this zone is presence of perforating veins through the muscle wall of 
the esophagus linking the submucosal and paraesophageal venous plexuses that 
are tributaries of the azygos venous system. These perforating veins run 
circumferentially around the esophageal wall. In PHT patients, dilated 
perforating veins become incompetent and allow retrograde blood flow from the 
paraesophageal to the submucosal veins. (4) The truncal zone is 8–10 cm long 
and is characterized by four of five longitudinal veins in the lamina propria. In 
this zone, perforating veins penetrate from the submucosa at irregular intervals 
to the external esophageal venous plexus. 
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Flow through the perforating veins is unidirectional toward the extrinsic plexus 
and systemic circulation. When portal hypertension develops, the valves of the 
perforating veins become incompetent and allow reversal of flow from the 
extrinsic to the intrinsic system. 
 
Varices of the gastroesophageal junction usually are classified by location as 
esophageal or gastric. Esophageal varices consist of three or four large trunks 
that are further characterized by size. The classification is important because the 
larger the varix, the more likely it is to bleed. Gastric varices, on the other hand, 
are by convention classified only by location. 
 
Pathphysiology of portal hypertension : 
 
Portal venous pressure is directly related to portal venous blood flow and 
resistance through the liver as described by Ohm’s law, i.e., P = Q x R, where P 
is pressure along a vessel, Q is the flow, and R is the resistance to the flow. 
Portal hypertension may result from both increases in flow and in resistance. 
Resistance is due to architectural distortion and regenerating nodules which 
cause resistance to the portal blood flow. There is an active intrahepatic 
vasoconstriction that accounts for 20-30% of the increased intrahepatic 
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resistance,56 which is mostly due to a decrease in the endogenous production of 
nitric oxide.57,58 Endothelin-1 also contributes to increased  intrahepatic 
vasoconstriction in PHT by enhancing hepatic stellate cell contractility. Clinical 
trials of endothelin receptor blockers in treatment of PHT are underway. Other 
vasoconstrictive mediators are angiotensin, thromboxane, and cysteinyl 
leukotrienes.  
 
In addition to resistance, increase in flow is also responsible for PHT. There is 
hyperdynamic circulation characterized by splanchnic vasodilatation, reduced 
mean arterial pressure, and increased portal blood flow. 
 
Figure 1 - Schematic representation of the pathophysiology of portal 
hypertension: 
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Figure 2 - Factors modulating intrahepatic resistance in cirrhosis: 
 
 
 
 
Classification of Portal Hypertension: 
The most useful classification of PHT is the anatomical classification, which 
categorizes it according to the site of pathology. Some causes and sites of the 
increased resistance are listed below: 
 Prehepatic 
o Splenic vein thrombosis 
o Portal vein thrombosis 
o Exrtrinsic compression of the portal vein 
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 Intrahepatic 
 Presinusoidal 
o Schistosomiasis 
o Primary biliary cirrhosis 
o Idiopathic portal hypertension 
o Noncirrhotic portal fibrosis 
o Congenital hepatic fibrosis 
 Sinusoidal 
o Alcoholic cirrhosis 
o Cryptogenic cirrhosis 
o Postnecrotic cirrhosis 
o Alcoholic hepatitis 
 Postsinusoidal 
o Veno-occlusive disease of liver  
 Posthepatic 
o Budd-Chiari syndrome 
o Thrombosis of Inferior Vena Cava 
o Constrictive pericarditis 
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Pathophysiology of variceal Hemorrhage and prediction of variceal 
hemorrhage:   
In cirrhosis, PHT is aggravated by the increase in the portal venous inflow due 
to splanchnic vasodilatation. When portal pressures rise, blood flow is diverted 
to venous collaterals that dilate to form vairces. All cirrhotic patients with 
varices do not experience bleeding episodes. Bleeding occurs in only about 
30%. Various factors including physical factors such as the elastic properties of 
the vessel and the intravariceal and intraluminal pressure are important 
determinants of whether rupture will occur. The likelihood that any one varix 
will rupture and bleed depends on its wall tension. Variceal wall tension is 
determined by the application of Poiseuille’s and Laplace’s laws. 
 
 
Figure 3 - Laplace’s Law applied to esophageal varices - factors interact 
in the pathophysiology of variceal bleeding.  
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In practice, this means that a large(R), long varix with a high flow rate and a 
thin wall is most likely to rupture and bleed. Thus, Highest risk of first 
hemorrhage (15% per year) occurs in patients with large varices.6 Other 
predictors of hemorrhage are decompensated cirrhosis (Child B/C) and the 
endoscopic presence of red wale marks (raised red streaks) and cherry red 
spots.6  Hemodynamic measurements of portal pressure including hepatic vein 
pressure gradient (HVPG), intravariceal pressure, and Doppler ultrasound are 
the valuable predictors for the same. Rebleeding usually occurs within the first 
6 weeks after an initial bleed.  
 
 
Figure 4- Variceal bleeding is the final step of a chain of events initiated by an 
increase in portal pressure, followed by the development and progressive 
dilation of varies until these finally rupture and bleed 
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Because it is not feasible to shorten a varix or increase its wall thickness, 
therapies for PHT aim to decrease variceal flow. This decrease is achieved by 
reducing either portal venous inflow (e.g., by splanchnic vasoconstriction) or 
resistance to portal outflow (e.g., by creation of a shunt). 
 
Natural History varices:  
 
The natural history of varices in cirrhotic patients with PHT evolves from a 
patient without varices to the development of varices and variceal bleed. 
Varices and variceal hemorrhage are a direct consequence of PHT. Patients with 
varices almost invariably have a portal pressure ( as determined by the hepatic 
venous pressure gradient [HVPG] of at least 12 mmHg, while normal HVPG is 
3-5 mmHg.7,59  Gastroesophageal varices occur in 50% of patients with 
cirrhosis, at the time of  diagnosis. Their presence correlates with the severity of 
liver disease; Almost 40% of Child A patients have varices, compared to 85% 
of Child C patients.60 Patients without varices develop them at a rate of 8% per 
year.10,61,62 Initially varices are small, but they enlarge with increasing blood 
flow. Variceal hemorrhage occurs at yearly rate of 5-15%.  In cirrhotic patients 
80-90% of bleeding episodes are due to variceal hemorrhage and one third of 
deaths in cirrhotic patients can be attributed to variceal hemorrhage. Although 
bleeding from esophageal varices ceases spontaneously in up to 40% of 
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patients, the mortality of an episode of variceal hemorrhage is of at least 20% at 
6 weeks, and it occurs mostly in patients with severe liver disease and in those 
with early re-bleeding. Late rebleeding occurs in approximately 60% of 
untreated patients within 1-2 years of the index hemorrhage.7, 63 
 
Table 1: Risk factors for early rebleeding 
Gastric varices 
Encephalopathy 
Alcoholic cirrhosis 
Large varices 
Active bleeding at endoscopy 
High HVPG 
                                                     
Diagnosis of Variceal bleeding: 
 
Early diagnosis of variceal bleeding is important, as early treatment of bleeding 
cat be lifesaving one. The gold standard in the diagnosis of varices is 
esophagogastroduodenoscopy (EGD). It confirms the variceal cause of bleeding 
and also determines the exact site of it. It also allows immediate management of 
the varices by banding or sclerotherapy. However, it should only be performed 
in a hemodynamically stable patient. Endoscopically varices are classified as 
per Paquet’s grading64 
Grade 1 –  Small varices without luminal prolapsed 
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Grade II – Moderate varices with luminal prolapsed and minimal obscuring of 
OG junction 
Grade III- Large varices substantially obscuring the OG junction. 
 
Screening for esophageal varices: 
 
There are no reliable methods of predicting which cirrhotic patients will have 
esophageal varices without endoscopy.43 The American Association for the 
Study of Liver Disease and the Baveno V Consensus Conference on portal 
hypertension recommended that all cirrhotic patients should be screened for the 
presence of EV when liver cirrhosis is diagnosed.22, 23  The optimal surveillance 
intervals for esophageal varices have not been determined. For patients found to 
have no varices on initial screening endoscopy, repeat endoscopy at 3-year 
intervals has been suggested, whereas patients with small varices should 
undergo endoscopy in 1-2 years.9, 24  Varices may grow faster in patients with 
cirrhosis secondary to alcohol abuse or severe liver impairment and in those 
with endoscopy stigmata of high risk (red wale markings); this subgroup of 
patients should undergo yearly upper endoscopy. 
 
Upper gastrointestinal tract endoscopy, which is the most common and accurate 
procedure for evaluation of varices, is at times inconvenient for patients.25,26  It 
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also bears a small risk of complications like esophageal perforation, aspiration 
of gastric contents and bacteremia.27,28  Moreover, sedation with 
benzodiazepines used for this procedure can significantly exaggerate hepatic 
encephalopathy.29   
 
Doppler ultrasonography is a non-invasive alternative method and may provide 
useful functional information. Many investigations reported correlations 
between different hepatic vasculature Doppler indices and the severity of portal 
hypertension and the resultant esophageal varices.20,35,44-50  Concerning 
abdominal ultrasound and Doppler studies, inter-observer and inter-equipment 
variability limit their applicability in clinical practice. Thus the current 
recommendation is that the accuracy of non invasive tests (Doppler ultrasound) 
for the diagnosis of PHT should be further assessed before their use can be 
recommended in clinical practice. As a consequence, upper GI endoscopy is the 
main tool used for screening and monitoring patients. 
 
Assessment of  Severity: 
 
The prognosis of the patient is best assessed by Child-Pugh criteria. If the total 
score is 5 or 6, cirrhosis is designated classA; if the score is 7-9, the cirrhosis is 
Class B; and if the score is ≥10,  the cirrhosis is class C. The prognosis is 
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directly related to the score. Further, higher the score , more are the chances that 
the patient will have varicel bleeding in near future. 
 
Table 2:  Child-Pugh Classification of Severity of cirrhosis 
Variable 1 point 2 point 3 point 
Encephalopathy Absent Mild to moderate Severe to coma 
Ascites Absent Slight Moderate 
Bilirubin (mg/dl) <2 2-3 >3 
Albumin (g/dl) >3.5 2.8 – 3.5 <2.8 
Prothrombin time 
(seconds above 
normal 
1-4 4-6 >6 
 
 
Hemodynamic measurement of portal hypertension: 
 
The evaluation of patients with portal hypertension is based on the visualization 
of varices at endoscopy, definition of the portal collateral anatomy and portal 
vein hemodynamics by Doppler ultrasonography or angiography, and the 
measurement of portal pressure. 
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A. Measurement of Portal Pressure 
 
Measurement of portal pressure is still the single most important hemodynamic 
measurement in portal hypertension. Portal pressure should be expressed in 
terms of the pressure gradient between the portal vein and the IVC, which 
represents the perfusion pressure within the portal and hepatic circulation. 
Normal values of PPG are up to 5 mm Hg. 
 
Portal pressure can be assessed by direct or indirect methods. 
 
1. Direct measurement: 
Direct measurements of portal pressure are invasive investigations based on the 
surgical, percutaneous transhepatic, or transvenous (transjugular) catheterization 
of the portal vein. Measurement of splenic pulp pressure and direct 
measurement of the portal vein pressure are invasive, cumbersome, and 
infrequently used approaches. Esophageas variceal pressure also can be 
measured but is not routinely performed in clinical practice. 
 
2. Indirect measurement: 
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The indirect and safe approach of hepatic vein catheterization, with 
measurements of the wedged hepatic venous pressure (WHVP) and free hepatic 
vein pressure (FHVP) and hepatic vein pressure gradient (HVPG) is the 
preferred technique to estimate portal pressure. The FHVP, measured when the 
tip of the catheter is maintained “free” in the hepatic vein, is close to the IVC 
pressure. WHVP is obtained by placing a catheter in the hepatic vein and 
wedging it into a small branch or by inflating a balloon and occluding a larger 
branch of the hepatic vein. The WHVP has been shown to correlate very closely 
with portal pressure in cirrhosis.65 
 
The HVPG is the difference between the WHVP and FHVP. The HVPG has 
been validated as the best predictor for the development of complications of 
PHT. The normal HVPG is 3-5 mmHg. HVPG has to be above 10 mm Hg for 
varices to develop and above 12 mm Hg for variceal bleeding. The threshold 
values define “clinically significant portal hypertension.”59, 61 HVPG is helpful 
in determining the cause of PHT, like presinusoidal, sinusoidal, or 
postsinusoidal because HVPG is normal in presinusoidal cause of PHT. It is 
also helpful to monitor patients in prevention of variceal bleeding. If HVPG 
decreased below 12 mmHg with therapy, variceal bleeding is prevented and 
varices decrease in size. It has also been shown that a reduction of 20% or more 
in HVPG (even if the HVPG remains more than 12 mmHg) is associated with a 
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reduction in the risk of variceal bleeding. The achievement of these targets also 
lowers the risk of ascites, hepatic encephalopathy, and death.66  However, the 
Baveno IV consensus states that routine use of HVPG cannot be recommended, 
because of its invasiveness.67 
 
B. Assessment of portal hemodynamics by Color Doppler Ultrasound:  
 
Because HVPG cannot be recommended for routine clinical practice for 
assessing PHT and upper GI endoscopy is somewhat inconvenient and not cost 
effective for assessing esophageal varices, various attempts have been made to 
find less invasive techniques to assess severity of PHT and its correlation with 
development of esophageal varices. Doppler ultrasonography is a non-invasive 
alternative method for assessing PHT. Many investigations reported correlations 
between different hepatic vasculature Doppler indices and the severity of portal 
hypertension and the resultant esophageal varices. 20,35,44-50   It is widely used to 
explore the relationship between EV hemodynamic associated with PHT and 
cirrhosis.68,69  Several Doppler ultrasonographic parameters have been measured 
to assess PHT such as Liver and spleen sizes, portal and splenic vein diameters, 
portal vein mean velocity (PVV), hepatic artery resistive index (HARI), hepatic 
artery pulsatility index (HAPI),  portal vein cross sectional area, Splenic artery 
resistive index (SARI), presence of portal-systemic collaterals and following 
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indices have been calculated : liver vascular index (LVI), congestion index (CI), 
portal hypertension index (PHI) 
 
1. Liver and Spleen Sizes: 
 
Liver size is determined by measuring the longitudinal length from the dome of 
the right lobe to the inferior end on the midclavicular line. USG may reveal 
changes of cirrhosis such as coarsened echo texture with or without altered 
echogenicity, nodularity of liver surface, presence of regenerating nodules and 
reduction in the number of visible portal or hepatic veins. Reduction of liver 
size with a combination of segmental hypertrophy and atrophy is seen. A 
caudate to right lobe ratio>0.65 and reduction of the transverse diameter of 
segment IV, i.e., left wall of gallbladder to ascending portion of left portal vein 
to less than 30 mm has been reported.70  Splenic size is found by measurement 
of its longest diameter. If splenomegaly is absent, PHT is unlikely though not 
ruled out. 
 
2. Portal and Splenic Vein Diameters: 
 
The normal portal vein diameter is 9-12 mm in quiet respiration. A portal vein 
diameter of >13 mm indicates portal hypertension with a high degree of 
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specificity but low sensitivity and a calibre over 17 mm is 100% predictive for 
large varices.71  Normal portal vein dimensions, however, do not exclude PHT. 
Portal vein diameter is done at the centre of the portal vein at a known angle of 
insonation less than 60˚. This is usually done 1 cm proximal to its bifurcation. 
Measurement of portal vein diameter is performed from the hilar segment, 
which has least interobserver variability. 
 
Splenic vein diameter is measured at the splenic hilum. The upper limit of 
normal splenic vein ranges from 10-12 mm with the vessel become prominent 
in PHT. 
 
3. Portal flow direction, velocity, and waveform: 
 
The normal portal flow is always directed towards the liver (hepatopedal) and 
has a fairly uniform flow velocity with slight phasicity in the spectral tracing 
secondary to respiration, and to a lesser extend cardiac activity. The fasting 
mean flow velocity is approximately 12-18 cm/sec (range12-23cm/sec) and has 
respiratory cycle variation decreasing on inspiration and increasing on onset of 
expiration. In normal subjects, the average portal flow is 500-900 ml/min.72 
Flow velocity is measured from the hilar segment with subjects in the supine 
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position and during inspiration. All subjects are examined by the intercostal 
route. Flow measurements consisted of peak, lowest, and mean venous velocity. 
Measurement of a cross-sectional area of the vessel lumen is done by showing it 
in a transverse plane. Flow direction recorded from both the main portal vein 
and right and left branches of it. Flow direction of the splenic vein is established 
to evaluate the flow direction in the portal system. Mean velocity should be 
calculated over tracing 4-6sec long in order to avoid fluctuation in flow 
velocity. As PHT develops, the flow velocity in the portal vein decreases and 
the flow in the portal vein lose its undulatory pattern and becomes monophasic. 
As severity of PHT increases, flow becomes biphasic and finally hepatofugal. A 
decrease in the portal venous flow velocity (<12 cm/s) is a characteristic 
feature of PHT.73,35,44-46  Both the volume flow and velocity are affected by the 
development of collaterals. Koda et al74 showed that a decrease in PVV is more 
sensitive than portal vein flow volume for the advancement of fibrosis stage. 
 
4. Hepatic Artery: 
 
The normal hepatic artery (HA) supplies only about 25% to 30% of blood to the 
liver. It lies anterior to the portal vein and measures about 4.6 mm. In a fasting 
patient, HA has a systolic velocity of 10-15 cm/sec. HA diastolic velocity 
normally is less than the peak portal vein velocity of about 18 cm/sec. If HA 
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diastolic velocities greater than the portal vein, cirrhosis should be considered. 
Measurements of the right HA are taken where it crosses the portal vein near the 
porta  hepatis. The hepatic artery is evaluated via an intercostal approach by 
demonstration of right and left portal veins under a 60° angle. Resistive and 
pulsatility index values are measured in the intrahepatic main branches.  
 
 The resistive index (RI) of the HA in a fasting subject varies from 0.55 to 0.81 
(mean 0.62-0.74). HARI increases in normal subjects after a meal.50,75  The 
pulsatility index (PI) of the HA varies from 1.16 to 1.24 in normal subjects. The 
RI and PI of the hepatic artery are increased in chronic liver disease due to an 
increase in intrahepatic vascular resistance. The most commonly used 
measurement is the HARI which is an indirect estimation of the impedance of 
arterial flow into the liver. In patients with advanced hepatic cirrhosis and 
chronic hepatitis, the normal increase in RI after a meal is also absent. The 
HARI falls steadily following acute portal vein thrombosis. 
 
Doppler impedance indices of spleen such as splenic artery resistive index 
(SARI) measured in the intraparenchymal branches of splenic artery, which is 
increased in patients with cirrhosis. Zhang et al.  demonstrated that HAPI 
(P=0.036), SARI(0.046) are closely correlated with PHT.76 
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5. Doppler Indices for PHT: 
 
(A) Liver vascular Index (LVI) :  
 
LVI= PV velocity / HARI, aids in the diagnosis of cirrhosis and PHT. A LVI 
less than 12 cm/sec identified cirrhosis and PHT with a specificity of 97% and a 
sensitivity of 93%.77  LVI in the patients with PHT was reduced compared with 
that in the healthy control subjects. This illustrates that patients with PHT are 
incapable of activating the hepatic artery to maintain liver perfusion. 
 
(B) Congestive Index (CI):  
  
Indirect assessment of portal pressure can be made using the congestive index. 
CI correlates with portal pressure or with portal resistance. The CI is the ratio 
between the cross sectional area and the mean flow velocity of portal trunk. It 
takes into account the fact that in PHT, the portal vein tends to dilate and blood 
velocity to decrease, so that higher values are found in patients with more 
severe portal resistance, pressure and larger varices. CI above 0.13 cm/sec has 
67% sensitivity in predicting PHT.  Haag et al.78 used the congestion index (CI) 
of the portal vein, exceeding 0.1 cm/s-1 to diagnose PHT. The CI reflects the 
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portal vascular outflow resistance and was sensitive for the diagnosis of PHT at 
0.08 cm/s-1 with 100% specificity.76 
 
(C) Portal Hypertensive Index (PHI) : 
 
Piscaglia et al.79 proposed a PHI cut-off of 1.2 s/m as the parameter with the 
highest accuracy (≈75%) for PHT. PHI is considered a comprehensive index, 
concerned with both intrahepatic and extra hepatic hemodynamic changes. PHI 
in the patients with PHT was significantly higher than that in the control group; 
the results of resistance from both upstream blood flow and intrahepatic blood 
flow increased. 
 
With the use of PVV and the HAPI, HARI, Splenic Artery RI, liver vascular 
index (VI), congestion index (CI), portal hypertension index (PHI) are 
calculated. Table 3 shows various Doppler indices measured. 
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Table 3   Indices, Their Explanations, and Units Used in the study 
Index Explanation Unit 
PVV80 Peak venous velocity in portal vein Cm/sec 
PV Dm Portal vein diameter cm 
PV CSA Portal vein cross sectional area Cm2 
HARI81 Hepatic Artery Resistive Index = (peak systolic 
velocity – end diastolic velocity)/peak systolic 
velocity 
* 
HAPI81 Hepatic Artery Pulsatility Index = (peak systolic 
velocity – end diastolic velocity)/time-averaged peak 
velocity 
* 
SARI82 Splenic Artery Resistive Index * 
LVI83 Liver vascular index = PVV / HAPI * 
CI84 Congestive index = PVCSA(cm2) / PVV * 
PHI83 Portal hypertensive index = 
(HARI*0.69)*(SARI*0.87) / PVV 
* 
*indices without units 
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6. Assessment of Hepatic Veins: 
 
Doppler spectral traces from normal hepatic veins have a triphasic appearance, 
consisting of two large antegrade waves that represent atrial and ventricular 
diastole and a small retrograde wave that occurs in atrial systole.77 Altered 
hepatic vein waveforms are seen in atleat 50% of patients with cirrhosis with 
flattening of the phasic oscillations. 
 
7. Portosystmic venous collaterals : 
Portosystmic venous collaterals are a clear indication of PHT. Ultrasonagraphy 
is reported to visualize 65-90% of collaterals. The important collaterals are Left 
gastric, short gastric vein, Paraumbilical vein, Splenorenal collaterals, 
collaterals within the gallbladder, splenoretroperitoneal, splenocaval, 
omphaloiliocaval, splenoportal. 
 
Correlation between portal vein doppler indices and EV: 
 
Tarzamni et al. showed that most of the echo-Doppler parameters were related 
to presence of EV and Portal vein flow velocity and liver vascular index was 
significantly higher in patients with EV while they had lower portal vein 
diameter, CI, portal hypertensive index, and hepatic and splenic artery RI.83 
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In study of Korner, the overall sensitivity for prediction of variceal bleeding in 
case of decreased portal vein mean velocity was 88% and that of its reduced 
volume flow was 65%.45  Iwao et al.50 Proposed LVI for the diagnosis of PHT 
and also showed significant association between low PVV, High HAPI in 
patients with large EV. Comparisons of the correlations between resistive 
indices and portal pressure showed that the HARI had the highest linear 
correlation with portal pressure. HAPI & LVI has weaker correlation and no 
significant correlations are present in the SARI.76 
 
Haktanir et al. demonstrated that mean HARI and HAPI values were 
significantly larger and Portal and splenic vein diameters and spleen sizes of 
patients with cirrhosis were significantly greater than those of the Chronic Viral 
Hepatitis and control groups. LVI and Mean PVV of the cirrhosis group was 
smaller than those in the control and CVH groups (P < 0.001).86 
 
C. Other Non-invasive Markers predicting esophageal varices: 
 
Various studies have shown that different biochemical, clinical and 
ultrasonographic parameters alone or together have good predictive power for 
non-invasively assessing the presence of EV. They  include splenomegaly, 
30,33,37,87-89 
 thrombocytopenia,30,33,34,37,87-90 ascites,33,88,  hepatic encephalopathy,33 
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serum albumin concentration,90  serum bilirubin levels,90 and Child–Turcotte–
Pugh (CTP),88,89  Model for End-stage Liver Disease (MELD),91 AST to platelet 
ratio index (APRI).91 
 
 In a study by Amarapurkar N et al. splenomegaly was detected in 86.7% of 
patients with liver cirrhosis, and it was 89.7% sensitive in predicting the 
presence of esophageal varices in patients with cirrhosis.36  Various authors 
have reported similar findings of an enlarged spleen being associated with the 
presence of varices.26,30-34,37 
 
Ismail et al. showed the presence of EV could be predicted by MELD score 
higher than 8 points (sensitivity: 80.10%; specificity: 51.20%; P=0.02) and 
APRI higher than 1.64 (sensitivity: 56.70%; specificity: 69.80%; P=0.01).91  He 
also demonstrated that platelet count <91,000, palpable splenomegaly, splenic 
size of 158 mm, hemodynamic instability, cirrhosis with hepatocellular 
carcinoma, and a previous history of gastroesophageal variceal hemorrhage are 
indicators of large EV.92 
 
Giannini A et al used platelet count/spleen diameter ratio cut off value of 909 
had 100% negative predictive value for a diagnosis of EV. He showed the 
platelet count/spleen diameter ratio seems to represent an acceptable surrogate 
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with highest accuracy for clinically relevant portal hypertension and for non-
invasively predicting the presence of EV.89 
 
AST to platelet ratio index  (APRI) values higher than 1.64 were correlated with 
the presence of EV, because they indicate more severe hepatic parenchymal 
architectural distortion and increased intrahepatic resistance, resulting in  
PHT.91  Sanyal et al. studied 1016 clinically stable cirrhotic patients and 
reported a correlation between high values of APRI, low platelets count and 
elevated AST, and the presence of EV.93  Sebastiani et al. found a weak 
correlation between APRI and the presence of any EV (APRI=1.4; sensitivity 
54%; specificity: 69%) and large varices.94  In a recent study by Tafarel et al. 
showed that presence of large EV require prophylactic therapy, could be 
predicted by MELD score higher than 8 points (sensitivity 80.1%;specificity 
51.2%:p=0.02), APRI higher than 1.64 (sensitivity 56.7%; specificity 69.8% 
p=0.01) and thrombocytopenia of 93,000/mm3 or less (sensitivity 56.1%; 
specificity 61.2%, p<0.01).91 
 
Schepis F et al.26 recommends endoscopic examination in liver cirrhosis with 
prothrombin activity below 75%, platelet count is less than 1,00,000/uL, and 
portal vein diameter exceeds 13 mm on ultrasound examination. Zaman et al.31 
in their study, found that a platelet count less than 88,000/uL significantly 
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predicts the development of esophageal varices. Chalasani et al.30 in a 
multivariate analysis found thrombocytopenia (< 88,000/uL) and splenomegaly 
to be strong predictors of esophageal varices. Giannini et al, in their study in 
Italy in 2003, found a cut off point of platelet count > 112,000 (p= 0.0001; 95% 
CI 0.815 – 0.928), splenic diameter > 121 mm (p= 0.0001; 95% CI 0.850 – 
0.951).89  Prihatini J etal. used platelet count of equal to or less than 82,000/uL, 
portal vein diameter of 11.5 mm or more, and an anteroposterior splenic 
measurement of 103 mm or more to detect esophageal varices in liver 
cirrhosis.20  Fook-Hong Ng et al. recommends endoscopic screening in liver 
cirrhosis in the presence of thrombocytopenia (<150,000/ul) or ascites.33 
 
Treatment of acute variceal hemorrhage: 
 
Treatment of variceal bleeding can be divided into immediate and definitive 
treatment. The goals of the treatment are: Control of acute bleeding, Prevent 
rebleeding by reducing portal pressure in patients who are at risk and by 
obliterating the varices, Prevent initial bleeding if possible in patients with 
diagnosed varices. 
 
Regarding nonspecific management, immediate treatment includes admission in 
ICU,  correction of hypovolemia with crystalloids(isotonic saline solution), 
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tracheal intubation for airway protection prior to endoscopy, blood volume 
replacement with the goals of maintaining hemodynamic stability and a 
haemoglobin level of approximately 8 g/dl.67 Current guidelines recommend 
prophylactic antibiotic therapy for cirrhotic patients admitted with acute variceal 
hemorrhage and should be instituted form admission.67  The recommended 
antibiotic schedule is norfloxacin 400 mg BD for 7 days or ceftriaxone (2 g/day) 
in advanced cirrhosis.43   
 
The recommended specific management consists of the combination of 
endoscopic therapy plus a safe vasoactive drug (terlipressin or analogues, 
somatostatin or analogues). The advantage of these drugs is that they can be 
started at admission and before diagnostic/therapeutic endosocopy and 
continued for 2-5 days to prevent early variceal rebleeding. Baik et al.95 
suggested that 2 mg IV terlipressin may be of greater benefit than somatostatin 
and its analogues. Although both drugs decreased HVPG significantly, the 
effect of terlipressin was sustained over the 25 minutes, while the effect of 
octreotide was transient. 
 
Regarding the best endoscopic therapy for the control of acute variceal 
hemorrhage, a meta-analysis of 10 randomised controlled trials shows an almost 
significant benefit of Endoscopic Variceal band Ligation (EVL) in the initial 
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control of bleeding compared to sclerotherapy.96 HVPG increased significantly 
immediately after both EVL and sclerotherapy, and it remained elevated for 5 
days for sclerotherapy group, while HVPG had decreased to baseline levels by 
48 hours after EVL.97 Therefore in the Baveno consensus report, EVL is the 
recommended form of endoscopic therapy for acute esophageal variceal 
bleeding although sclerotherapy is recommended if EVL is technically 
difficult.67 Failures of initial therapy with combined pharmacological and 
endoscopic therapy are best managed  by a second attempt at endoscopic 
therapy or, in the case of fundal gastric varices, by transjugular intrahepatic 
portosystemic shunt (TIPS).67 
 
Prevention of recurrent variceal hemorrhage: 
Either combination pharmacological therapy (nonselective b-blockers plus 
nitrates) or EVL are considered the therapy of choice in the prevention of 
variceal re-bleeding. The choice depends on tolerance and local expertise. 
However, with either of these therapies, re-bleeding rates are still quite high 
(30%-42% in studies of b-blockers plus nitrates; 20%-43% with EVL).63 The 
lowest re-bleeding rates of 7%-13% have been described in studies on 
pharmacological therapy in which HVPG decreased by >20% from baseline or 
to levels below 12 mmHg. 63 Randomized controlled trials show combining EVL 
and b-blockers significantly reduces re-bleeding rates than EVL alone.98,99 
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Additionally, 1-year variceal recurrence was lower in the EVL+nadolol group 
(54%) than in the EVL alone group (77%). Therefore the current 
recommendation is still to use EVL+b-blocker± nitrates as first line therapy. 
Side effects of EVL include hemorrhage from ulcers, chest pain, dysphagia, and 
odynophagia. Because gastric acid may exacerbate post-EVL ulcers, acid 
suppressors may reduce EVL related side effects. 
 
In patients who fail combined endoscopic and pharmacological treatment for 
prevention of re-bleeding, TIPS or surgical shunts should be considered, 
depending on local availability and the surgical candidacy of the patient. 
Patients with decompensated cirrhosis are not candidates for shunt therapy and 
should be evaluated for liver transplantation. 
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MATERIALS AND METHODS 
 
Ninety nine Cirrhotic patients registered in liver clinic and admitted in ward 
(both old and new patients), Dept. of medical gastroenterology, Govt. Stanley 
medical college were included in this prospective study. The study period from 
April 2010 to January 2012. All subjects included in the study provided 
informed consent to participate. The study was approved by the Ethics 
Committee of our institution. All patients underwent a detailed clinical 
evaluation at entry, with the following data: 
Age, Gender, Duration of illness, Details of treatment prior to registration. 
Etiology of cirrhosis was arrived based on history of alcohol intake including 
quantity & total duration of consumption; blood for viral serology (HBsAg 
&HBV DNA assay for hepatitis B and HCV RNA & Anti-HCV for hepatitis C); 
serum ceruloplasmin (<20mg%), presence of Kayser Fleischer ring and 24 
hours urine copper estimation (>100mg%) for Wilsons disease; and antinuclear 
antibody, hypergammaglobulinemia (>3.5 gm%) for autoimmune related 
cirrhosis.  
 
Apart from details of past blood transfusion, surgery, family members with liver 
disease, details of associated co-morbid illness were also recorded.  
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Relevant history and physical characteristics including symptoms and signs of 
liver failure (spider angioma, palmar erythema etc.), hepatomegaly, 
splenomegaly, and abdominal vein collaterals were recorded. Ascites was 
graded as none, mild (detectable only on ultrasound), moderate (visible 
moderate symmetrical abdominal distension) or severe (marked abdominal 
distension).  Hepatic encephalopathy was graded from grade 0 to IV, as per the 
Conn's grading.  Diagnosis of cirrhosis was based on clinical, biochemical, and 
ultrasonographic findings.   
 
Exclusion criteria: 
1. Patients with evidence of hepatocellular carcinoma on ultrasonography 
2. Portal vein thrombosis 
3. Previous H/O surgical intervention for portal hypertension 
  
Blood tests: 
 
Hematological and biochemical workup included measurement of hemoglobin, 
total leukocyte count, platelet count, prothrombin time, and serum 
concentrations of bilirubin (total and conjugated), protein, albumin, alanine 
aminotransferase and aspartate aminotransferase. All patients were tested for 
HBsAg and antibodies to hepatitis C virus to determine the cause of liver 
42 
 
cirrhosis. Tests for other causes of cirrhosis (serum ceruloplasmin and slit lamp 
examination for Wilson's disease, tests for autoantibodies for autoimmune liver 
disease, iron studies for hemochromatosis) were carried out only if there was a 
suggestive clinical clue. For each patient, a modified Child-Pugh score was 
calculated. 
 
Child Turcotte  Pugh (CTP) score was applied to grade the severity of cirrhosis. 
CTP score is based on serum bilirubin, serum protein, ascites, prothrombin time 
and hepatic encephalopathy. Minimum score of CTP is 5 and maximum score is 
15. Based on scoring system, cirrhosis was classified as Childs A when the total 
score was 5 & 6, Childs B when the total score was 7 to 9, and Childs C when 
the total score is exceeded 9. 
 
Colour Doppler Ultrasound: 
All patients underwent ultrasonography and the following details were 
recorded: maximum vertical span of the liver; nodularity of liver surface; spleen 
size (length of its longest axis); diameter of the portal and splenic veins; 
presence of portal-systemic collaterals; and presence of ascites. All Doppler 
assessments were performed by a single radiologist using a 3.5 MHz curvilinear 
transducer of EASOATE MyLab40 (Germany) machine. Patients were 
examined while fasting and in supine position and quiet respiration. Subcostal 
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or intercostals ultrasonic windows were used to obtain longitudinal view of 
middle hepatic vein, portal vein and hepatic artery (in front of portal vein) with 
an ultrasound beam incidence angle of less than 60º. Outer-to-outer main portal 
vein diameter (mm) was measured in midway between the spleno-portal 
junction and its intrahepatic bifurcation.  
 
Several Doppler ultrasonographic parameters were measured such as Liver and 
spleen sizes, portal and splenic vein diameters, portal vein mean velocity 
(PVV), hepatic artery resistive index (HARI), hepatic artery pulsatility index 
(HAPI),  portal vein cross sectional area, Splenic artery resistive index (SARI), 
presence of portal-systemic collaterals and following indices were calculated : 
liver vascular index (LVI), congestion index (CI), portal hypertension index 
(PHI). 
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Table 3: Indices, Their Explanations, and Units Used in the study 
Index Explanation Unit 
PVV80 Peak venous velocity in portal vein Cm/sec 
PVDm Portal vein diameter cm 
PV CSA Portal vein cross sectional area Cm2 
HARI81 Hepatic Artery Resistive Index = (peak systolic 
velocity – end diastolic velocity)/peak systolic 
velocity 
* 
HAPI81 Hepatic Artery Pulsatility Index = (peak systolic 
velocity – end diastolic velocity)/time-averaged peak 
velocity 
* 
SARI82 Splenic Artery Resistive Index * 
LVI83 Liver vascular index = PVV / HAPI * 
CI84 Congestive index = PVCSA(cm2) / PVV * 
PHT83 Portal hypertensive index = 
(HARI*0.69)*(SARI*0.87) / PVV 
* 
*indices without units 
 
Endoscopic  evaluation: 
 
All patients underwent upper gastrointestinal endoscopy for assessment of 
esophageal and gastric varices after Doppler ultrasound examination. If EVs 
were present, their size was graded as I-IV, using the Paquet grading 
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system. Grade 0: No varices, grade I: Varices, disappearing with insufflation, 
grade II: Larger, clearly visible, usually straight varices, not disappearing with 
insufflation, grade III: More prominent varices, locally coil-shaped and partly 
occupying the lumen, grade IV: Tortuous, sometimes grape-like varices 
occupying the esophageal lumen.64 Further, patients were classified 
dichotomously either as having large EVs (grade III-IV) or as not having these 
(no varices) or small EV (grade I-II). Presence of gastric varices, portal 
hypertensive gastropathy, and duodenopathy were recorded wherever 
appropriate.  
 
Statistical analysis: 
 
Data were analyzed with Analysis of Variance (ANOVA) Technique. 
Descriptive statistics including means, standard deviations, and frequencies 
were computed. For determining associations, univariate analysis was 
performed by ANOVA.  A p value less than 0.05 was considered statistically 
significant. A multivariate ordinal logistic regression (OLR) model was used for 
determining the adjusted associations between size of esophageal varices and 
hepatic hemodynamic determinants. 
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RESULTS 
 
Ninety nine cirrhotic patients (70 men, 29 women) were enrolled in the study. 
Mean age of the study population was 44 ± 11.5 years. Cirrhosis was 
predominantly observed in men (Male: Female - 2.4:1). Table 1 shows the 
patients’ baseline characteristics. 
Table 4: Demographic characteristics of the study population 
Characteristics No (%) 
Total No of cases 99 
Mean age (years) 44+11.5 
Gender distribution  
Male 70 (71%) 
Female 29 (29%) 
Literacy status  
Yes 78 (79%) 
No 21 (21%) 
Alcohol Ingestion  
Yes 43 (43% 
No 56(57%) 
Smoking  
Yes 33(33%) 
No 66(67%) 
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Figure 5: Gender distribution 
 
 
Figure 6: Alcohol and Smoking pattern 
 
 
Alcohol related liver disease constitutes the most common etiology of cirrhosis 
in our study followed by cryptogenic and Hepatitis B related liver disease. 
(Table 5) 
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Table 5: Etiology of cirrhosis 
Etiology n % 
Alcohol 32 29.63% 
Alcohol+Hepatits B 8 7.41% 
Alcohol+Hepatits C 2 1.85% 
Autoimmune 2 1.85% 
Cryptogenic 30 27.78% 
Hepatitis B 23 21.30% 
Hepatitis C 7 6.48% 
Wilsons disease 3 2.78% 
 
 
Figure 7: Etiology of cirrhosis 
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The severity of liver disease as assessed by Child Pugh scoring was: Child A in 
31%, Child’s B and C in 45% and 23% respectively. 
 
Table 6: Severity of liver disease as assessed by CTP score 
CTP Grade n % 
Grade A 31 31% 
     Grade B 45 45% 
Grade C 23 23% 
 Total 99 100% 
   
  
 
Table 7: Mean values of Laboratory investigation 
Investigation Mean Std dev 
Hb (gms%) 9.64 2.61 
Platelet Count(no.) 95818.18 42936.68 
PT (sec.) 18.49 4.64 
INR  1.42 0.40 
Creatinine (mg/dl) 2.23 13.48 
TB mg/dl) 2.60 2.74 
AST (U/L) 77.63 60.24 
Albumin (g/dl) 2.84 0.73 
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Figure 8:  Mean prothrombin time 
 
Table 8: Mean values of Doppler study parameters 
Doppler study Mean Std dev 
Liver size (cms) 11.98 1.45 
PV DM (cms) 1.20 0.26 
PV velocity 
(cm/sec) 12.97 4.60 
HARI 0.71 0.12 
HAPI 1.32 0.44 
PV cs area(cm2) 1.05 0.58 
Spleen Size 
(cms) 14.85 3.36 
SARI 0.67 0.08 
Liver Vascular 
Index 10.73 5.01 
Congestive 
Index 0.11 0.14 
PHT Index 0.05 0.11 
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Of the 99 patients, 19 (19%) did not have esophageal varices at endoscopy, 36 
(36%) had small esophageal varices (SEV) and 44 (45%) have large esophageal 
varices (LEV).  
Figure 9: Mean of different Doppler parameters 
 
Figure 10: Mean of significant Doppler parameters 
 
 
Table 9 shows the relationship of absence of EV or presence of SEV/LEV with 
various clinical, laboratory and ultrasonographic characteristics on univariate 
analysis. 
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Table 9: Comparison of different parameters according to Varices: 
Parameter 
No Varices 
(n=19) 
SEV (n=36) 
 
LEV (n=44) P-Value 
 
MELD 11.00± 4.22 14.39±5.59 12.39±4.94 0.500 
Platelet 
Count 
114578±53732 95333±44346 78113±34290 0.049* 
PT(sec) 16.53±4.33 19.90±4.59 18.18±4.55 0.030* 
INR 1.34±0.37 1.48±0.37 1.41±0.43 0.490 
TB (mg/dl) 1.94±1.86 3.25±3.09 2.35±2.69 0.176 
AST (U/L) 83.74±69.87 78.94±47.42 73.91±66.06 0.830 
PV Velocity 
(cm/sec) 
15.44±4.63 12.96±4.90 11.91±3.97 0.019* 
HARI 0.67±0.08 0.74±0.15 0.71±0.09 0.108 
HAPI 1.13±0.34 1.38±0.53 1.35±0.38 0.117 
PV cs area 
(cm2) 
1.08±0.78 0.98±0.51 1.10±0.55 0.638 
Spleen Size 
(cm) 
13.34±4.20 15.10±2.56 16.29±3.42 0.05* 
SARI 0.71±0.09 0.66±0.07 0.67±0.08 0.092 
Liver 
Vascular 
Index 
14.38±5.56 10.46±4.99 9.38±4.01 0.001* 
Congestive 
Index 
0.10±0.13 0.11±0.14 0.12±0.15 0.816 
PHT Index 0.04±0.06 0.03±0.03 0.06±0.16 0.444 
P/S Ratio 957.00±607.54 668.86±343.94 627.68±325.51 0.011* 
APRI 0.07±0.04 0.10±0.07 0.11±0.12 0.288 
53 
 
Six factors were found to be significantly different between the three groups. 
These were Platelet count (P=0.049), Prothrombin time (P=0.030), Portal vein 
velocity (P=0.019), Liver vascular index (P=0.001), Spleen size (P=0.05) and 
Platelet count/spleen ratio (P=0.011). No significant difference is observed for 
the other parameters. 
 
Figure 11: Mean PV Velocity in three groups 
 
Figure 12: Mean Liver Vascular Index in the three groups 
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Figure 13: Comparison of significant Doppler parameters according to EV 
 
Figure 14: Mean P/S Ratio in the three groups 
 
Figure 15:  comparison of significant noninvasive parameters according to EV 
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Table 10 shows the results of a logistic regression analysis in 99 patients.  In 
this analysis no factors found to have independent predictive value for the 
presence of LEV. 
Table 10: Logistic Regression Results: 
Variables P-Value Odds Ratio 
Group A 0.440 1§ 
Group B 0.761 1.778 
Group C 0.360 5.511 
MELD 0.559 0.880 
Hb  0.904 0.975 
Platelet 0.794 1.000 
PT 0.047 0.692 
INR 0.055 185.554 
TB 0.764 0.915 
AST 0.182 1.041 
PV_DM 0.609 0.344 
PV_Velocity  0.214 1.161 
HARI 0.596 62.255 
HAPI 0.613 0.393 
PV_CS 0.764 1.333 
Spleen size  0.114 0.692 
SARI 0.053 168 
Liver_Vascular index 0.315 1.212 
Congestive_Index 0.271 19.845 
PHT_Index 0.429 10.125 
P/S_Ratio 0.568 0.999 
APRI 0.175 0.000 
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DISCUSSION 
 
Variceal gastrointestinal bleeding is a major complication of portal hypertension 
with significant morbidity and mortality. However, this complication occurs 
primarily in patients with LEV and is uncommon in those with small varices. 
Because the occurrence of variceal bleeding can be prevented using 
pharmacological agents like beta-adrenergic receptor antagonists, it is important 
to recognize patients who have LEV and are thus at a higher risk of developing 
variceal bleeding and likely to benefit from such interventions. It has therefore 
been recommended that patients with liver cirrhosis should be screened for the 
presence of LEV at the time of initial diagnosis and at periodic intervals 
thereafter throughout life. Efforts have been made to identify clinical, laboratory 
and imaging characteristics that may non-invasively predict the presence or 
absence of LEV with a high degree of accuracy, either reducing or eliminating 
the need for screening endoscopy. Few data have been published on predictors 
of LEV from India. Differences in the predictors found to be significant in 
various previous studies indicate that such studies may be necessary in our 
population. Such studies may be particularly indicated because of differences in 
the etiology of liver disease with a larger proportion of Indian patients being 
related to viral infections, the greater severity of liver disease in our patients 
because of their delayed presentation, and poorer nutritional status. 
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Our study, based on information achieved from 99 liver cirrhosis patients from 
tertiary care centre in south India, including 44 with LEV, showed that 6 factors 
had predictive ability for the presence of LEV on univariate analysis. These 
were Platelet count (P=0.049), Prothrombin time (P=0.030), Portal vein mean 
velocity (P=0.019), Liver vascular index (P=0.001), Spleen size (P=0.05) and 
Platelet count/spleen ratio (P=0.011). However, on multivariate analysis, no 
factors were found to have independent predictive value.  
 
Our study population was composed mainly of patients with liver cirrhosis due 
to alcohol abuse or chronic hepatitis B infection, which represent more than 
50% of the causes of liver cirrhosis, followed by cryptogenic in 27%. 
 
In our study, there was no correlation between the presence of EV and CTP 
classification. These findings were also reported by other researchers, 31, 37, 92   
but in a study by zaman et al. showed CTP class B or C were nearly 3 times 
more likely to have varices on endoscopy than CTP class A.34 
 
MELD score also was not a good predictor of the presence of EV or LEV in our 
study. Burton et al.100 and Levy et al.101 also demonstrated no predictive value 
for MELD for the presence of EV. But in a recent study by Tafarel et al.91 
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showed that the presence of EV could be predicted by MELD score higher than 
8 points (sensitivity 80.1% and specificity 51.2%). 
 
The importance of platelet count has been alluded to in many studies. 30,33,34,37,87-
90
  The values of thrombocytopenia related to the presence of EV were different 
among various published studies. 
 
Table 11: Comparison of platelet count in various studies 
Study Small varices Large varices P value 
Zaman et al.34 107000 76000 0.001 
Thomopoulos et al.88 126000 81000 <0.0001 
FH Ng et al.33 160000 110000 0.01 
Madhotra R et al.37 94000 62000 0.0003 
Chalasani et al.30 - <88000 0.0001 
Giannini et al.89 177000 79000 <0.0001 
Ismail et al.92 113000 91000 0.028 
Tafrel et al.91 116000 90000 <0.01 
Prihatini et al.20 161000 101000 0.003 
Sharma SK et al.87 118000 84000 0.002 
In this study 95000 78000 0.049 
59 
 
In our study platelet count less than 95000/mm3 was associated with the 
presence of SEV and platelet count less than 78000/mm3 associated with the 
presence LEV. This is in line with existing studies that have documented LEV 
with platelet count less than 100000/mm3. Thrombocytopenia and EV are 
associated because both resulted from deterioration of liver functional reserve, 
leading to hemodynamic changes.  
 
In our study, patients with LEV group had large spleen size (16.29±3.42 cm) in 
comparison to those in SEV (15.10±2.56cm) & no varices (13.34±4.20 cm) 
group with p =0.05.  In the only available Indian study, Amarapurkar et 
al.36 found that presence of splenomegaly was associated with presence of 
esophageal varices but not with LEV. In our study, LEV were more often 
associated with a splenomegaly (size>162mm, p=0.05) as has been observed in 
other parts of the world. 
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Table 12:  comparison of Association of spleen size with presence of EV in 
various studies 
Study No 
varices 
Small 
varices 
Large 
varices 
P value 
Thomopoulos et al.88 - 131 mm 152 mm 0.032 
FH Ng et al.33 - 102 mm 117 mm 0.02 
Madhotra R et al.37 - 31% 62% 0.0001 
Chalasani et al.30  - - 75% 0.05 
Giannini et al.89 - 110 mm 155 mm <0.0001 
Ismail et al.92 - 115 mm 158 mm 0.032 
Amarapurkar N et al.36 17.9% 44% 37.7%  
Prihatini et al.20 - 101 mm 123 mm 0.007 
In this study 133 mm 151 mm 162 mm 0.05 
 
The presence of splenomegaly in cirrhotic patients is likely the result of 
vascular disturbances that are mainly related to portal hypertension. Even 
though low platelet count and splenomegaly were used as important predictors 
of presence of EV, the use of platelet count alone as a non-invasive predictor of 
EV can be misleading and cannot be solely attributed to portal hypertension. In 
patients with chronic liver disease the presence of decreased platelet count may 
depend on several factors other than portal hypertension, such as shortened 
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platelet mean lifetime, decreased thrombopoietin production, or myelotoxic 
effects of alcohol or hepatitis viruses. In this situation Giannini et al. 89 
introduced a new parameter, platelet count/spleen diameter (p/s) ratio. He 
showed that platelet count/spleen diameter ratio with cut off value of 909 had 
100% negative predictive value for non-invasively predicting the presence of 
EV in patients with either compensated or decompensated liver cirrhosis. 100% 
of patients with a p/s ratio >909 were free from EV. The platelet count/spleen 
diameter ratios represent an acceptable surrogate marker for clinically relevant 
portal hypertension. In concordance with the study by Giannini et al.89 our study 
also showed similar results. 
 
Table 13: comparison of Platelet/spleen diameter ratio for predicting EV 
Study No varices SEV LEV P value 
Giannini et al. 1638 - 533 <0.0001 
In our study 957 668 627 0.011 
 
 
In our study, prothrombin time predicts the presence of LEV in univariate 
analysis. But no other study demonstrated prothrombin time as a predictor of 
EV. 
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Among the hemodynamic characteristics of portal vein and hepatic artery, our 
study showed the Mean portal vein velocity (15.44±4.63 vs. 12.96±4.90 vs 
11.91±3.97, p=0.019), and Liver vascular index (14.38±5.56 vs. 10.46±4.99 vs. 
9.38±4.01, p=0.001) were the predictors of EV in univariate analysis. There was 
a significant association between the mean portal vein velocity and the size of 
varices (p = 0.019). According to Korner et al. the overall sensitivity for 
prediction of variceal bleeding in case of decreased portal vein mean velocity 
was 88%. Although none of other portal vein measurements had statistically 
significant associations with the size of varices, some articles have shown that 
portal vein diameter is also increased in large varices,20,47 such a finding was not 
observed in our study. Iwao, et al, showed that not only portal venous velocity 
was significantly lower, but the hepatic arterial pulsatility index was also 
significantly higher in patients with esophageal varices.50 Our study results did 
not disclose any significant associations between hepatic artery resistive index,  
pulsatility index and esophageal varices status. Various authors like Liu et al,102 
Shabestari et al.85, Zhang et al.76 also demonstrated no predictive value of 
HARI, HAPI, SARI for the presence of EV. 
 
In a recent study by Tarzamni et al.83 Portal vein diameter, congestion index 
(CI) (0.11 ± 0.03 vs. 0.06 ± 0.03, P < 0.0005), portal hypertensive index (2.62 ± 
0.79 vs. 1.33 ± 0.53, P < 0.0005), and hepatic (0.73 ± 0.07 vs. 0.66 ± 0.07, P < 
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0.001) and splenic artery resistance index (SARI) (0.73 ± 0.06 vs. 0.62 ± 0.08, P 
< 0.0005) were found to be significantly higher in patients with LEV and portal 
vein flow velocity (13.25 ± 3.66 vs. 20.25 ± 5.05, P < 0.0005), liver vascular 
index (8.31 ± 2.72 vs. 17.8 ± 6.28, P < 0.0005) were significantly lower in 
patients with LEV. A logistic regression model confirmed spleen size 
>15.05cm, (P = 0.002) and portal hypertensive index (P = 0.040) as independent 
predictors for the occurrence of large esophageal varices (LEV). Our study 
correlates only with liver vascular index and portal vein velocity which was 
significantly lower in patient with LEV. 
 
Table 14: Comparison Doppler parameters of our study with Tarzamni et al.83 
Studies Tarzamni et al.83 In our study 
Parameters No EV LEV P value No EV LEV P value 
PVV 
(cm/sec) 
15.26 ± 5.06 12.13 ± 2.59 0.001 15.44±4.63 11.91±3.97 0.019 
PV DM 
(mm) 
13.24 ± 2.55 14.54 ± 1.48 0.037 12.4±2.6 13.6±1.8 0.609 
HARI 0.70 ± 0.06 0.80 ± 0.06 0.003 0.67±0.08 0.71±0.09 0.108 
Spleen size 
(cm) 
15.21 ± 2.99 17.62 ±3.1 0.003 13.34±4.20 16.29±3.42 0.05 
SARI 0.69 ± 0.06 0.76 ± 0.11 < 0.0005 0.71±0.09 0.67±0.08 0.092 
LVI 10.96 ± 5.05 6.48 ± 2.78 < 0.0005 14.38±5.56 9.38±4.01 0.001 
CI 0.09 ± 0.03 0.14 ± 0.04 < 0.0005 0.10±0.13 0.12±0.15 0.816 
PHTI 2.14 ± 0.77 3.18 ± 0.90 < 0.0005 0.04±0.06 0.06±0.16 0.444 
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Piscaglia et al79 proposed a PHI cutoff of 1.2 s/m as the parameter with the 
highest accuracy (≈75%) for PHT and useful tool for detecting esophageal 
varices. Our study did not show significant association between PHI and 
esophageal varices. 
 
Shabestari et al.85 showed significant correlation between the size of esophageal 
varices and portal vein mean velocity (p=0.04) and logistic regression analysis 
did not show any significant associations between Doppler parameters and the 
size of esophageal varices. He also concluded that none of hepatic vasculature 
Doppler measurements had a significant role in predicting the size of 
esophageal varices. 
 
Table 15: Comparison Doppler parameters of our study with Shabestari et al.85 
Studies Shabestari et al. In our study 
Parameters No EV LEV P 
value 
No EV LEV P value 
PVV 
(cm/sec) 
15.5 (10.8-20.2) 10.47 (6.6-14.4) 0.08 15.44±4.63 11.91±3.97 0.019 
PV DM 
(mm) 
11.2 (9.9-12.5) 11.4 (9.3-13.5) 0.38 12.4±2.6 13.6±1.8 0.609 
HARI 0.69 (0.60-0.79) 0.71 (0.68-0.75) 0.83 0.67±0.08 0.71±0.09 0.108 
HAPI 1.46 (1.05-1.87) 1.38 (1.18-1.6) 0.70 1.13±0.34 1.35±0.38 0.117 
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De Bem, et al.48 also revealed that there is no good correlation between Doppler 
ultrasound parameters of the portal system and the presence of gastroesophageal 
varices in cirrhotic patients. According to Liu et al.102  mean PVV (P =0 .001), 
SARI (P =0.04), were predictive of the presence of esophageal varices at 
univariate analysis, but in multivariate logistic regression analysis, only mean 
PVV was independently associated with the presence of esophageal varices.  
 
Table 16: Comparison Doppler parameters of our study with Liu et al.102   
Studies Liu et al. In our study 
Parameters No EV LEV P value No EV LEV P value 
PVV 
(cm/sec) 
14.7±3.2 16.9±3.7 <0.001 15.44±4.63 11.91±3.97 0.019 
HARI 0.75±0.06 0.76±0.08 0.42 0.67±0.08 0.71±0.09 0.108 
HAPI 1.54±0.27 1.60±0.39 0.18 1.13±0.34 1.35±0.38 0.117 
SARI 0.71±0.06 0.69±0.07 0.04 0.71±0.09 0.67±0.08 0.092 
 
Our study is also in line with the above studies, in which portal vein diameter, 
HARI, HAPI, SARI, congestive index, portal hypertensive index did not predict 
the presence of esophageal varices. Multivariate logistic regression analysis did 
not show any significant association between Doppler parameters and 
esophageal varices.  
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SUMMARY 
In the present study, 
1. The most common etiology of cirrhosis in this part of country is Alcohol 
related liver disease (29%), followed by cryptogenic and Hepatitis B 
related liver disease (28% & 21% respectively). 
 
2. Non-invasive parameters like Platelet count (P=0.049), Prothrombin time 
(P=0.030), Platelet count/spleen diameter ratio (P=0.011) predicted the 
presence of large esophageal varices. 
 
3.  Among the Colour Doppler Ultrasound study parameters, the Portal vein 
mean velocity (P=0.019), Liver vascular index (P=0.001), Spleen 
size>16.2 cm (P=0.05) predicted the presence of  large esophageal 
varices, increasing the risk for upper gastrointestinal bleeding. 
 
4. Other non-invasive parameters like CTP score, MELD, AST/Platelet 
ratio, Bilirubin, and Doppler parameters like portal vein diameter, hepatic 
artery resistive & pulsatility index, splenic artery resistive index, 
congestive index, portal hypertensive index did not predict the presence 
of either small or large varices. 
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CONCLUSION 
 
In conclusion, results of our study indicate that  non-invasive tools like platelet 
count, prothrombin time, platelet/spleen diameter ratio, spleen size >16.2 cm, 
and Doppler parameters like portal vein velocity, liver vascular index are 
predictors of presence of large esophageal varices.  
 
But there were no independent noninvasive predictors of large  esophageal 
varices by multivariate analysis in our study. Values for the noninvasive 
indicators from this study and comparables need to be validated by randomised 
prospective studies. 
 
Applying the non-invasive techniques including hepatic vessel hemodynamics 
by Doppler study for the detection of esophageal varices and assess the risk for 
bleeding may be cost effective and safer than the “scope all strategy”. But 
further randomised studies are needed to evaluate the accurate predictors of 
esophageal varices in our population. Till then Upper Gastrointestinal 
endoscopy remains the gold standard procedure for screening esophageal 
varices and assessing risk for bleeding. 
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ABBREVIATIONS 
 
PHT                     - Portal Hypertension 
EV           - Esophageal varices 
SEV   - Small esophageal varices 
LEV   - Large esophageal varices 
PPG   - Portal Pressure Gradient 
CTP   - Child Turcot Pugh  
MELD  - Model for End stage liver disease 
HVPG                  - Hepatic vein pressure gradient 
WHVP  - Wedged Hepatic vein pressure  
FHVP          - Free hepatic vein pressure  
PVV   -Portal Vein Velocity 
PV DM  -Portal vein diameter 
PV CSA  -Portal vein cross sectional surface area 
HARI   - Hepatic Artery Resistance Index 
HAPI   - Hepatic Artery Pulsatility Index 
SARI   - Splenic Artery Resistive Index 
LVI   - Liver Vascular Index 
CI   - Congestive Index 
PHI   - Portal Hypertension Index 
P/S   - Platelet count / Spleen diameter ratio 
APRI   - AST/Platelet Ratio Index 
CVH   - Chronic Viral Hepatitis 
TIPS   -Transjugular intrahepatic portosystemic shunt 
EVL   -Endoscopic Variceal band Ligation 
HBsAg  -Hepatitis B surface Antigen 
HBV DNA  -Hepatits B Virus Deoxyribonucleic acid 
Anti HCV  -Anti Hepatits C virus  
HCV RNA  -Hepatitis C virus Ribonucleic Acid 
  
 
 
 
 
 
CODING FOR MASTER CHART 
 
1. Sex                                       -  1- Male, 2- Female 
2. Literacy                         -  1- Literate, 2-Illiterate 
3. Alcohol consumption          – 1-Yes, 2- No 
4. Smoking                          - 1-Yes, 2- No  
5. CTP class                             - 1-Class A, 2- Class B, 3-Class C 
6. Ascites                 - 1-Present, 2- Absent 
7. Hepatic Encephalopathy      - 1-Present, 2- Absent 
8. HRS         - 1-Present, 2- Absent 
9. SBP         - 1-Present, 2- Absent 
10. Coagulopathy       - 1-Present, 2- Absent 
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1 Jayaraman 56 1 579/12 Alcohol 1 1 1 9 2 16 1 2 2 2 2 1 7.6 105000 19 1.4 1.69 1.2 63 2
2 Noor basha 55 1 428/12 Alcohol 1 1 1 8 2 6 1 2 2 2 2 2 9.9 217000 14 1 0.65 0.9 60 2
3 Nagendran 45 1 640/12 Alcohol 1 1 1 14 3 26 1 1 2 2 1 1 5.9 138000 31 2.4 0.84 14.3 65 1.6
4 Ramadass 44 1 3573/10 Hepatitis B 1 2 2 6 1 8 2 2 2 2 2 1 9.6 81000 15 1.1 0.98 1.3 130 3.2
5 perumal 56 1 7035/11 Hepatitis B 1 2 2 5 1 11 2 2 2 2 1 2 6.9 85000 20 1.5 0.85 1.03 21 3.7
6 Ravi 45 1 6052/11 Alcohol+Hepatits B 1 1 2 10 3 17 1 1 2 2 2 1 12.8 85000 16 1.3 1.07 6.1 128 2.8
7 Chokkalingam 32 1 6642/11 cryptogenic 1 2 2 9 2 10 1 1 2 2 1 2 10.4 49000 19 1.4 0.59 0.68 45 2.3
8 Sathish 33 1 204/12 Alcohol 1 1 2 11 3 22 1 2 2 1 1 2 10 96000 27 1.8 0.69 10 297 2
9 Jaganathan 43 1 707/12 Hepatitis B 1 2 2 9 2 18 1 2 1 2 2 2 8.5 72000 18 1.3 1.86 2.1 91 2
10 Kali 48 1 275/10 Hepatitis B 2 2 1 10 3 16 1 2 2 2 1 1 10.9 99000 22 1.6 0.65 3 123 2
11 Sekar 35 1 4804/10 Alcohol 1 1 1 5 1 11 2 2 2 2 2 1 14.6 50000 19 1.4 0.62 1.2 36 3.6
12 Dhivakar 28 1 6840/10 Alcohol 1 1 2 6 1 15 2 2 2 2 2 1 10.7 192000 17 1.2 0.3 5.09 137 3.5
13 Sivalingam 53 1 6700/11 Hepatitis C 1 1 2 7 2 10 1 2 2 2 2 1 10.3 60000 19 1.4 1 1 73 2.5
14 Visalatchi 70 2 5010/10 cryptogenic 2 2 2 8 2 10 1 2 2 2 2 1 7.1 155000 15 1.1 0.7 1.9 51 2.2
15 Panch peer 42 1 6538/04 cryptogenic 1 2 2 6 1 9 1 2 2 2 2 1 11.2 99000 16 1.2 0.8 1.2 49 3.9
16 Sakkiya banu 18 2 3515/09 cryptogenic 1 2 2 8 2 9 1 2 2 2 2 2 7.4 29000 15 1.1 0.7 1.5 27 2.3
17 Vasudevan 51 1 4439/10 Hepatitis B 1 2 2 6 1 11 1 2 2 2 2 1 9.3 162000 16 1.1 1.02 0.9 51 3.6
18 Srinivasan 18 1 3678/10 cryptogenic 1 2 2 9 2 16 1 2 2 2 2 1 6.3 90000 20 1.5 0.5 3.7 72 3.1
19 Rosy 47 2 4196/01 cryptogenic 1 2 2 6 1 8 2 2 2 2 2 1 5.8 70000 18 1.2 0.7 0.6 40 2.4
20 Palani 55 1 312/11 alcohol 2 1 1 8 2 7 2 2 2 2 2 2 7.2 79000 20 1.9 0.9 1.2 65 2.1
21 Kokila 28 2 474/11 cryptogenic 1 2 2 5 1 9 2 2 2 2 2 1 10 100000 18 1.3 0.53 0.8 36 3.7
22 Stellamary 43 2 6249/11 cryptogenic 1 2 2 8 2 7 1 2 2 2 2 1 2.6 24000 16 1.1 0.6 0.2 24 1.2
23 Gunasekar 54 1 2609/11 Hepatitis B 1 1 1 7 2 10 2 2 2 2 2 2 12.8 50000 17 1.2 0.95 1.6 82 2.8
24 Ramani 22 2 5650/11 cryptogenic 1 2 2 6 1 6 1 2 2 2 2 2 12.1 26000 14 1 0.6 0.4 32 4.3
25 Vargese 50 1 259/10 Hepatitis B 1 2 2 9 2 12 1 1 2 1 1 1 10.6 91000 19 1.4 0.6 1.6 122 2.4
26 Rajasekar 60 1 3089/11 Hepatitis B 1 1 1 6 1 8 2 2 2 2 2 1 12.6 88000 14 1 1.19 0.5 74 2.8
27 Malligabegam 46 2 285/11 Hepatitis B 2 2 2 7 2 9 1 2 2 2 2 2 10.1 109000 16 1.1 0.9 1.4 23 2.6
28 Chakkarapani 25 1 4869/10 Hepatitis B 1 2 2 7 2 15 2 2 2 2 2 2 8.7 71000 30 2.2 0.75 1 70 2.4
29 Sekar 42 1 6702/11 Alcohol 1 1 1 7 2 13 1 2 2 2 1 1 8.9 88000 19 1.5 0.9 1.8 75 2.9
30 Anusuya 60 2 3403/09 Hepatitis C 2 2 2 10 3 20 2 2 2 2 2 1 4.5 54000 24 2 1.2 2.8 67 2.1
31 Nagaraj 42 1 510/11 Alcohol 2 1 1 10 3 16 1 1 2 2 2 1 12.3 61000 18 1.2 0.98 5.2 121 2.6
32 Venkataraman 49 1 5217/11 Alcohol 2 2 1 7 2 14 1 2 2 2 2 1 7.9 87000 21 1.5 1.37 0.5 69 2.8
33 Sakunthala 45 2 2265/07 cryptogenic 2 2 2 5 1 10 2 2 2 2 2 1 10.9 100000 16 1.4 1 1 35 3.9  
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3 9.5 0.67 7.5 0.8 1.76 0.2 17.4 0.76 4.26 0.03 0.049 2 603 0.1
1 12.3 0.9 10.8 0.64 1.09 0.36 10.17 0.71 9.91 0.033 0.03 2 213 0
2 12.7 1.6 18.3 0.5 0.8 1.42 12.91 0.7 22.9 0.078 0.011 2 1070 0.1
3 12.6 1.25 10.7 0.69 1.13 0.55 21.5 0.56 9.47 0.05 0.022 1 377 0.2
3 11.8 1.3 8.4 0.64 1.2 1.4 17.2 0.64 7 0.167 0.029 2 494 0
3 11.5 1.43 6.9 0.8 1.55 0.69 14.4 0.57 4.45 0.1 0.04 2 590 0.2
2 10 0.65 9.1 0.75 1.75 0.05 19 0.73 5.2 0.0054 0.036 1 251 0.1
2 11.9 0.7 6 0.8 1.74 0.07 14.9 0.67 3.45 0.012 0.053 1 644 0.3
2 9.8 0.8 12.2 0.65 1.15 0.14 16.8 0.6 10.61 0.011 0.019 1 429 0.1
2 10.2 1.03 13.6 0.78 1.25 0.67 14.2 0.72 10.88 0.049 0.025 1 697 0.1
2 13.5 1.12 8.4 0.56 0.95 1.07 21.8 0.53 8.84 0.127 0.173 2 229 0.1
3 13.9 0.86 14.1 0.78 1.5 1.14 14.4 0.61 9.4 0.99 0.017 1 1333 0.1
1 14.3 1.3 15 0.42 0.57 0.93 18.8 0.9 29 0.062 0.014 2 319 0.1
3 9.8 0.9 17.2 0.6 1.03 0.56 8.2 0.62 16.7 0.032 0.177 2 1890 0.3
2 12.6 1.2 10.3 0.8 2.5 1.58 20 0.69 4.12 0.153 0.032 2 495 0.1
1 12.3 1.9 15.2 0.75 1.5 3.72 23.2 0.94 10.1 0.24 0.028 2 125 0.1
3 14.3 1.1 9 0.5 0.7 0.54 13.7 0.6 12.8 0.06 0.005 2 1182 0
3 12.8 1.05 18.5 0.86 1.21 0.5 19.6 0.7 15 0.027 0.195 2 459 0.1
2 9.8 1.18 14.2 0.88 2.9 0.6 17.9 0.7 4.89 0.21 0.026 2 391 0.1
3 10.2 1.3 19.2 0.6 1.8 1.9 12.3 0.6 10.6 0.098 0.011 2 642 0.1
3 12 1.5 20 0.8 1.6 1.4 18.5 0.7 12.5 0.07 0.0163 2 540 0
3 12.9 1.2 10 0.61 1 1.85 16.5 0.74 10 0.185 0.27 1 570 0
3 11.5 1.15 13.4 0.5 0.67 1.08 20 0.53 20 0.081 0.0118 2 250 0.2
1 12.8 1.4 16.4 0.67 1 1.04 9.6 0.76 16.4 0.063 0.0186 2 2708 0
3 12.2 1.33 15.4 0.71 1.14 0.66 16.2 0.76 13.51 0.043 0.021 2 562 0.1
3 9.9 1.4 7.5 0.68 1.2 0.92 11.9 0.62 6.25 0.123 0.035 2 740 0.1
1 10.5 1.27 14.5 0.75 1.32 0.37 11.8 0.68 10.9 0.026 0.0211 2 924 0
2 10.6 1.19 6.6 0.57 0.92 0.45 16.7 0.6 7.17 0.068 0.0311 2 425 0.1
3 11.5 1 20 0.6 1.1 0.39 10 0.6 18.2 0.0195 0.0104 2 880 0.1
3 12.3 1.03 13.3 0.73 1.5 0.63 9.7 0.75 8.9 0.047 0.024 1 557 0.1
2 14.3 1.24 10.7 0.78 1.9 1.39 13.4 0.72 5.63 0.129 0.032 2 455 0.2
3 13.4 1.3 15 0.68 1.36 1.34 15.7 0.64 11.03 0.091 0.017 2 554 0.1
3 13.8 1.3 7 0.8 2.15 2.5 15.6 0.6 3.25 0.36 0.041 2 641 0  
33 Sakunthala 45 2 2265/07 cryptogenic 2 2 2 5 1 10 2 2 2 2 2 1 10.9 100000 16 1.4 1 1 35 3.9
34 Divya 18 2 4413/08 cryptogenic 1 2 2 5 1 9 2 2 2 2 2 1 10.8 100000 14 1.2 0.8 1.2 20 4
35 Thanikaivel 40 1 6955/11 Alcohol 1 1 2 10 3 21 2 2 2 2 2 2 8.6 255000 28 2 135 2.9 88 1.8
36 Pandian 52 1 5113/11 Alcohol 2 1 2 7 2 11 1 2 2 2 2 2 10.2 95000 21 1.5 0.7 0.9 45 3.1
37 Palayam 45 1 1227/11 cryptogenic 1 2 2 7 2 7 2 2 2 2 2 1 6.3 42000 15 1 0.63 1.2 29 3.2
38 Sathiakumar 42 1 362/08 cryptogenic 1 2 2 5 1 10 2 2 2 2 2 1 6 61000 16 1.4 1.1 0.8 46 3.9
39 Sharmila banu 35 2 3165/07 cryptogenic 1 2 2 5 1 9 2 2 2 2 2 1 11.8 61000 14 1.3 0.9 0.8 26 4.4
40 Yasin 22 2 4823/11 wilsons 1 2 2 8 2 12 2 2 2 2 2 2 7.6 90000 16 1.2 0.6 2.6 102 2.7
41 Mumtaj begum 33 2 444/09 cryptogenic 1 2 2 6 1 7 2 2 2 2 2 1 12.2 100000 16 1.1 0.7 1 40 3.2
42 Palani 37 1 622/12 Alcohol 1 1 2 10 3 12 1 2 2 2 2 1 7.7 80000 17 1.7 0.8 2.9 58 2.3
43 Thameem 22 1 3651/11 cryptogenic 1 2 2 6 1 10 2 2 2 2 2 1 12.6 84000 16 1.1 1 2 24 3.9
44 Malleswari 40 2 1103/06 cryptogenic 1 2 2 5 1 19 2 2 2 2 1 1 9.8 78000 37 2.8 0.52 1.2 79 2.8
45 Elumalai 23 1 3848/09 Alcohol 1 1 2 7 2 13 1 2 2 2 2 2 12.3 120000 18 1.6 0.9 1.6 89 3.1
46 Nedunchelian 56 1 7538/10 Hepatitis B 1 1 2 5 1 9 2 2 2 2 2 1 7.2 144000 16 1.2 0.9 1.2 76 3.7
47 Rajendran 65 1 4088/11 Alcohol 1 1 1 7 2 12 1 2 2 2 2 2 11 100000 14 1.2 1.2 1.7 96 2.8
48 Vasantha 42 2 630/06 Hepatits C 2 2 2 6 1 11 2 2 2 2 2 2 5 130000 16 1.4 0.8 1.3 24 3.2
49 Anthonysamy 66 1 n Alcohol 1 1 2 6 1 13 1 2 2 2 2 1 10.2 130000 14 1.6 1.2 0.6 52 4.2
50 Kamali 35 2 1532/06 cryptogenic 1 2 2 6 1 8 1 2 2 2 2 2 9 110000 14 1.2 0.8 0.8 21 3.6
51 Sampoornam 58 2 5706/09 cryptogenic 2 2 2 10 3 17 1 2 2 2 1 2 8.4 24000 25 1.8 0.7 3 79 2.1
52 Kahimunizha 26 2 4125/11 cryptogenic 1 2 2 8 2 22 2 2 2 2 1 1 6.8 50000 30 2.9 0.7 0.9 27 3.4
53 Prabu 30 1 272/10 Alcohol 1 1 1 9 2 6 1 2 2 2 2 1 16 142000 14 1 0.9 2.5 444 2.1
54 Mangalam 16 2 5687/11 Wilsons 1 2 2 11 3 19 1 2 2 2 1 2 8.1 180000 31 2.3 0.6 2.3 123 2.4
55 Baskar 46 1 3155/09 cryptogenic 1 2 2 6 1 10 1 2 2 2 2 2 9.2 57000 16 1 0.78 1.3 62 4.2
56 Koteeswari 52 2 442/07 Autoimmune 2 2 2 5 1 10 2 2 2 2 2 1 7.4 120000 16 1.3 1 1.3 23 3.6
57 Govardhanam 47 1 6156/10 Alcohol 1 1 2 8 2 10 1 2 2 2 2 1 13.3 97000 15 1 0.87 2.5 77 3.5
58 Zakir 43 1 154/10 Hepatitis B 1 1 1 8 2 11 1 2 2 2 1 2 6.9 100000 20 1.4 1.09 0.9 87 2.4
59 Jaffer 52 1 91/12 Alcohol 1 1 1 10 3 12 1 1 2 2 2 2 10.2 110000 15 1.5 1 1.2 55 1
60 Kumar 54 1 183/12 Hepatitis B 1 2 2 11 3 15 1 1 2 2 1 2 7.9 51000 19 1.4 1.08 2.8 54 2.3
61 Arumugam 38 1 222/12 Alcohol 2 1 1 8 2 23 2 2 2 2 1 1 4.8 64000 27 2.1 0.92 8.3 83 3.8
62 Albert xavier 52 1 5908/11 Alcohol 1 1 2 8 2 30 2 2 2 2 1 1 6.2 69000 24 2.1 2.7 4.6 72 3.7
63 Mohandass 64 1 6470/10 cryptogenic 1 2 2 11 3 18 1 1 2 1 1 1 5.5 59000 20 1.8 0.9 3.8 54 4.1
64 Chandra 40 2 6282/09 cryptogenic 2 2 2 7 2 6 1 2 2 2 2 2 8.9 92000 17 1 0.7 1 46 3.2
65 Gunasekaran 49 1 6642/09 Alcohol 1 1 1 10 3 22 1 2 1 2 1 1 12.4 112000 18 1.3 1.39 11.9 82 2
66 Ethiraj 51 1 5550/09 Hepatitis B 2 2 2 9 2 19 1 2 2 2 1 2 10.2 79000 20 2.1 1.1 2.2 45 3.2  
3 12.9 1.02 5.6 0.72 1.37 0.56 20.5 0.54 4.09 0.1 0.041 2 488 0
2 14.2 1.1 16.9 0.74 1.23 0.92 13.7 0.71 13.7 0.054 0.019 2 1861 0
3 12.5 1.13 12.3 0.69 1.24 1.15 13.24 0.76 9.91 0.093 0.0256 2 719 0.1
3 11.75 1.2 9.9 0.7 1.5 1.42 10.8 0.64 6.6 0.143 0.0271 2 202 0.1
3 12.8 1.28 6.1 0.67 1.14 0.91 19.9 0.57 5.4 0.149 0.039 1 306 0.1
3 11.4 1.2 14.5 0.73 1.6 0.63 17.6 0.7 6.13 0.064 0.0313 1 347 0
1 13.11 1.63 19.7 0.57 0.99 2.12 10.5 0.74 19.9 0.108 0.0128 2 857 0.1
3 13 1.6 6.9 0.61 1.06 1.36 21.3 0.66 6.51 0.197 0.035 1 469 0
3 11.4 1.5 15.8 0.9 1.7 0.9 16.4 0.7 9.3 0.057 0.023 1 488 0.1
2 11.4 0.98 9.9 1.41 0.71 0.32 16.13 0.47 13.9 0.032 0.04 1 522 0
3 11.29 0.85 7.9 0.64 0.94 0.49 17 0.78 8.04 0.062 0.037 1 459 0.1
2 11.09 1.9 6.3 0.89 1.9 2.21 16 0.71 3.32 0.35 0.058 2 750 0.1
3 12 1.21 7.5 0.76 1.3 0.64 15.7 0.62 5.77 0.085 0.037 2 917 0.1
1 12.4 0.8 12.6 0.74 1.71 0.58 8.71 0.73 7.4 0.046 0.026 2 1149 0.1
1 10.3 0.9 16.3 0.79 1.9 0.3 12.7 0.67 8.58 0.018 0.019 2 1023 0
3 12.3 1.07 8.7 0.6 1.13 0.9 10.1 0.77 7.69 0.103 0.032 2 1287 0
1 11.7 1.64 23 0.7 1.45 1.58 14.3 0.66 15.9 0.069 0.012 1 769 0
2 10.8 1.34 8.9 0.79 1.8 1.45 20.8 0.56 4.9 0.162 0.029 1 115 0.3
3 10.8 1.43 11.8 0.65 1 2.11 19 0.69 11.8 0.179 0.023 1 263 0.1
3 11.2 1.3 10.6 0.78 1.1 1.5 13.4 0.72 9.64 0.142 0.031 1 1060 0.3
1 10.1 0.7 11 0.68 1.2 0.7 14.5 0.64 9.2 0.063 0.261 2 1241 0.1
3 11.4 1.24 12.6 0.87 2.1 2.14 15 0.66 6 0.169 0.027 1 380 0.1
3 8.6 1.7 12.8 0.7 2.2 1.62 17.8 0.7 5.82 0.127 0.023 1 674 0
3 12.1 0.92 13.9 0.8 2.28 0.41 13.6 0.83 6.1 0.029 0.0286 1 713 0.1
2 11.1 1.2 12.6 0.65 1.1 0.86 12.8 0.76 11.45 0.068 0.024 2 781 0.1
2 13 1.4 15 0.84 2.87 1.2 14.9 0.64 5.23 0.8 0.022 2 738 0.1
2 12.3 1.1 9.9 0.76 1.5 0.47 14.2 0.7 6.6 0.047 0.032 2 359 0.1
2 12.8 1 5.9 0.8 1.4 0.46 15.6 0.54 4.21 0.078 0.079 2 410 0.1
2 11.1 1 12.3 0.84 1.5 0.53 15.8 0.77 8.2 0.043 0.0315 1 437 0.1
3 12.8 1.1 17.5 0.7 1.34 0.89 13.1 0.72 13.06 0.051 0.017 1 450 0.1
2 12.3 0.6 18.3 0.8 1.4 0.67 16.1 0.66 13.07 0.037 0.017 2 571 0.1
3 11.4 1.18 14.9 0.78 1.6 1.6 15.2 0.7 9.3 0.107 0.022 2 737 0.7
3 12.2 1.3 10.1 0.77 1.2 1 13.4 0.56 8.4 0.099 0.026 1 940 0.1  
67 Jagadeesan 55 1 224/10 cryptogenic 1 2 2 8 2 15 2 2 2 2 1 2 9.9 130000 18 2 0.71 1.2 52 2.9
68 Jayalakshmi 50 2 5458/09 cryptogenic 1 2 2 7 2 10 1 2 2 2 2 1 8.9 64000 17 1.3 0.4 1.2 65 3
69 Rajendran 55 1 2005/10 Alcohol 2 1 1 7 2 8 1 2 2 2 2 1 11.2 148000 14 1 0.5 1.4 59 3.2
70 raja 39 1 4712/09 Alcohol 1 2 2 9 2 15 2 2 2 2 2 2 13.4 124000 16 1.1 0.8 8.1 142 2.5
71 srinivasan 35 1 6280/07 cryptogenic 1 2 2 6 1 7 2 2 2 2 2 2 14 150000 18 1.1 0.8 1 95 3.1
72 Jothi 55 1 240/10 Hepatitis B 1 2 2 6 1 8 2 2 2 2 2 2 9.1 84000 15 1.1 0.4 1.1 67 2.9
73 rosy 46 2 4916/07 cryptogenic 1 2 2 6 1 7 2 2 2 2 2 1 12.4 100000 16 1.1 0.7 0.9 80 3.2
74 Neelakandan 49 1 5664/10 Alcohol 1 1 1 7 2 9 2 2 2 2 2 1 13.6 99000 14 1 1.2 1.1 52 2.4
75 Murthy 59 1 4585/08 Hepatitis C 2 2 2 5 1 9 2 2 2 2 2 2 13 110000 13 1.1 1.1 1.3 78 3.8
76 Murugan 50 1 3006/09 Hepatitis B+Alcohol 1 1 1 6 1 10 2 2 2 2 2 2 14 140000 14 1.2 0.57 1.2 45 3.1
77 Krishnaveni 58 2 5988/10 Hepatitis B 1 2 2 7 2 8 1 2 2 2 2 2 9.2 105000 15 1.1 1 1.3 52 2.8
78 Dhanasekar 40 1 6037/10 Hepatitis B 1 2 2 7 2 8 1 2 2 2 2 2 11.4 135000 14 1 1 1.2 66 3.1
79 Raja 39 1 4712/10 Alcohol 1 1 1 9 2 19 1 2 2 2 1 2 14 134000 14 1.5 0.8 8.1 174 3.4
80 sivaprasad 46 1 4215/09 Alcohol 1 1 1 6 1 6 2 2 2 2 2 2 13.9 150000 17 1 0.6 0.9 143 3.1
81 srinivasan 35 1 6280/07 cryptogenic 1 1 1 5 1 7 2 2 2 2 2 2 13.8 153000 16 1.1 0.8 1 67 3.7
82 selvi 40 2 5335/09 Hepatitis C 1 2 2 8 2 10 2 2 2 2 1 2 12.4 100000 14 1.7 0.5 1.71 79 2
83 sudhakar 45 1 4941/09 Hepatitis B 1 2 2 8 2 10 2 2 2 2 1 2 8.9 77000 18 1.1 0.8 2 92 2.9
84 Adhinarayanan 50 1 1896/10 Hepatitis C+Alcohol 1 1 1 10 3 19 1 2 2 2 2 2 8.6 47000 18 1.3 0.71 12.4 105 2
85 Bagavathy 48 2 1208/10 Hepatitis B 2 2 2 9 2 16 2 2 2 2 2 2 5.3 64000 18 1.6 0.5 3.2 96 2.2
86 Dharanikkkarasi 42 2 932/10 Hepatitis B 1 2 2 6 1 7 2 2 2 2 2 2 10.2 65000 16 1.1 0.6 0.6 60 3
87 Indira 43 2 228/10 cryptogenic 1 2 2 8 2 14 2 2 2 2 1 2 10.1 45000 24 1.7 0.83 1.6 52 2.4
88 Ethiraj 48 1 7055/10 Hepatitis B 1 2 2 8 2 16 1 2 2 2 2 2 9.6 77000 16 1.6 0.9 3.3 84 3.6
89 Gajendran 52 1 1764/11 Alcohol 1 1 1 10 3 14 1 2 2 2 1 2 8.9 133000 19 1.3 1.23 2.4 43 2
90 Ganesan 55 1 1899/10 Hepatitis B+Alcohol 1 1 1 9 2 12 1 2 2 2 2 2 9.8 97000 19 1.3 0.98 2.2 89 2
91 Gajapathy raja 32 1 3040/10 Hepatitis B+Alcohol 1 1 1 10 3 19 1 2 2 2 1 2 9 89000 22 1.7 0.9 6 39 2.9
92 Kannan 40 1 1287/11 Hepatitis B+Alcohol 1 1 1 10 3 19 1 2 1 2 1 2 5.8 31000 25 1.9 1.31 2.3 57 2
93 Muthu 39 1 825/11 Alcohol 2 1 1 10 3 16 1 2 2 1 1 2 8.5 83000 25 1.8 0.76 2.2 148 2
94 Manokaran 56 1 264/11 Hepatitis B+Alcohol 1 1 1 11 3 18 1 2 2 2 2 2 10 217000 16 1.5 0.5 5.7 314 2
95 Murali 37 1 1468/06 Hepatitis B 1 2 2 8 2 14 2 2 2 2 2 2 8.2 49000 16 1.1 1.2 3.4 55 2.6
96 Noordeen 45 1 5146/10 Alcohol 2 1 1 12 3 18 1 1 2 1 2 2 7.7 149000 17 1.3 0.85 8.6 81 2.3
97 Pushpa 55 2 6429/09 Hepatitis C 1 2 2 9 2 11 1 2 2 2 2 2 10.2 71000 18 1.2 0.5 2.1 48 2
98 Ramu 48 1 4719/10 Alcohol 2 1 1 10 3 19 1 2 2 2 2 2 10.6 78000 23 1.6 0.5 6.7 54 2.4
99 Siva 41 1 1260/11 Hepatitis B+Alcohol 1 1 1 11 3 26 1 2 2 2 2 2 12.2 40000 28 2 1.7 6.7 170 2  
 
1 13.2 0.9 18 0.62 0.8 0.52 21 0.7 22.5 0.029 0.014 2 619 0
3 13 1.6 10 0.68 1.22 2.1 18 0.64 8.2 0.21 0.026 2 356 0.1
2 13.6 1.4 17.8 0.74 1.26 1.6 14.8 0.69 13.8 0.089 0.0166 1 1072 0
2 13 1.1 8 0.7 1.21 0.9 13 0.7 6.61 0.113 0.037 1 954 0.1
2 12 1.2 17.5 0.68 1.15 0.93 17.5 0.64 15.2 0.053 0.015 1 986 0.1
3 12.3 1.35 14 0.66 1.2 0.7 13 0.72 11.7 0.05 0.02 2 646 0.1
2 10.2 1.4 9.1 0.78 1.45 2.1 12.8 0.64 6.3 0.231 0.033 2 781 0.1
3 11.8 1.4 16 0.8 1.02 1.62 22 0.71 15.7 0.101 0.021 2 450 0.1
1 13 1.3 16.2 0.7 1.23 1.5 9.2 0.7 13.2 0.092 0.018 2 1195 0.1
2 13.7 1.21 14.5 0.66 0.78 1.42 13 0.68 18.5 0.097 0.019 2 1076 0
1 12 0.6 15 0.68 0.97 0.87 8.5 0.6 15.5 0.058 0.0163 2 1235 0.1
1 12.6 1.3 14.2 0.7 0.84 0.9 14.2 0.7 16.9 0.063 0.021 2 950 0.1
1 13 1.1 8 0.6 0.58 0.8 13 0.62 13.7 0.1 0.028 2 1030 0.1
1 15.2 1.1 15.4 0.65 1.1 0.85 11.2 0.66 14 0.055 0.0167 2 857 0.1
2 12 1.18 16.1 0.7 0.9 0.96 17.5 0.75 17.8 0.059 0.0195 2 1195 0
1 11.6 1.4 9.4 0.7 1.2 1.12 12.8 0.69 7.8 0.119 0.031 1 781 0.1
3 10.2 1.4 9.1 0.9 1.52 0.94 12.8 0.76 5.9 0.103 1.045 2 602 0.1
3 15.6 1.1 13.4 0.66 0.9 0.89 12.2 0.6 14.8 0.066 0.018 1 385 0.2
2 12.2 0.9 17.4 0.68 1.3 1.42 10.7 0.62 13.4 0.083 0.015 1 598 0.2
3 12.4 1.4 8.3 0.76 1.6 1.3 12.7 0.76 5.18 0.157 0.041 2 512 0.1
1 13.5 1.2 28 0.69 0.93 1.1 18 0.7 19.4 0.61 0.161 2 250 0.1
2 10 1.3 11.3 0.72 0.87 1.4 13.9 0.69 12.99 0.124 0.022 2 554 0.1
2 10.5 1.1 14.2 0.64 0.77 0.9 14.2 0.65 18.4 0.0803 0.0175 2 937 0
2 8 1.2 13.6 0.68 1.2 0.64 12 0.6 11.3 0.047 0.018 2 808 0.1
2 9.3 1.6 15 0.65 1.42 1.2 14.3 0.62 10.56 0.08 0.0161 2 622 0
2 10.9 1.2 12.6 0.7 1.3 1 13 0.67 9.7 0.08 0.022 1 238 0.2
2 13.4 1 17.5 0.6 1.21 0.98 11.6 0.63 14.5 0.056 0.0129 1 716 0.2
1 14.3 0.9 14.6 0.64 1.13 1.2 11.2 0.61 12.9 0.082 0.0161 2 1938 0.1
2 10.6 1.3 11.2 0.7 1.1 1.12 13.9 0.71 10.2 0.1 0.027 1 353 0.1
2 14.1 1.2 31.6 0.6 1.16 1.3 14.6 0.69 17.7 0.063 0.0121 2 1021 0.1
2 10.2 1.2 13.6 0.7 1.2 0.9 13.2 0.66 11.3 0.066 0.0203 2 538 0.1
3 14.4 1.1 12 0.69 0.98 1.2 12.9 0.6 12.3 0.1 0.021 2 605 0.1
3 11.1 1.6 8.7 0.7 1.48 1.27 13.4 0.56 5.87 0.145 0.027 1 299 0.4  
PROFORMA  
1. Name: 
2. Age : 
3. Sex : 
4. MGE No : 
5. Diagnosis : Cirrhotic 
6.   D.O.R: 
7.   Resident of:  Chennai / other city (specify) 
8.   Type of house:  pucca/hut/semi 
9.   Per capita income: 
10.Literacy status:  studied up to: no education/I-V/VI-VIII/IX- 
XII/college/professional/other courses 
11. Occupation (as such): 
12. No. of children: 
13. No. of adult family members: 
14.  Religion:  Hindu /Muslim /Christian/others (specify): 
15.  Smoker: - present/past/never 
              Duration of smoking in yrs: <1/1-<5/5-<10/ > 10-<20/>20 Yrs 
              Brand:- Beedi/Cigarette/combined 
16. Alcohol:- present/past/never 
 
Clinical details: 
 
1. History of bleed:  yes / no 
2. Duration of illness ( as such):   
3. Age at diagnosis (as such): 
4.  History suggestive of liver disease:  
5. Jaundice                                :  Yes / No; if yes for how long…… 
6. Oedema legs                         : Yes / No 
7.  Weight loss                          : Yes/No 
8. Weakness                              : Yes / No 
9. Ascites                                : Yes / No 
10. Hepatomegaly                       : Yes / No         
11. Splenomegaly                   :  Yes / No         
12. Investigations: 
Date  
 TC  
Hb  
Platelets  
PCV  
PT  
APTT  
INR  
Urea  
Sugar F/PP  
Creatinine  
Chloride  
Bilirubin T  
Bilirubin B  
Albumin  
Globulin  
AST  
ALT  
GGT  
S. Alk Phos  
S. AFP  
HBsAg  
Anti HCV  
 
13. Ascitic fluid analysis: 
 
 
14. UGI scopy: 
                     
Date    
Grades of varices 
 
   
Fundal varices    
PHG    
Endotheraphy 
 
   
 
15. Liver biopsy: as required 
 
16. USG abdomen:     
Liver Shrunken/large/normal size 
 Echotexture:  coarse / normal 
 Edges:  regular/irregular 
 Nodularity:  yes / No 
PV (mm) Diameter:  
 Direction of blood 
flow 
Hepatopetal 
 
Hepatofugal 
 
Pv velocity 
(cm/s) 
 
Hepatic artery 
Resistance index 
 
Liver vascular 
Index 
 
Congestion Index  
 
Portal 
hypertension 
index 
 
 
Spleen size (cm)  
Splenic artery 
Resistance index 
 
Ascities  Present/absent 
 17. Doppler indices: 
 
HARI = Systolic velocity – end diastolic velocity/systolic velocity 
Liver Vascular Index = Portal venous velocity/ HA pulsatility index 
Congestive index = PV cross sectional area/ PV velocity 
PHT index =( HARI*0.69)(SARI*0.87)/ PV mean velocity 
18. Platelet / Spleen diameter ratio : 
19. AST / platelet count ratio index: 
20. Treatment:-  
           
21. Follow up: 
 
22. Outcome: 
 
 
Date PV 
dm 
(cm) 
PV 
Velo
city 
(cm/s
e) 
HAR
I 
HA 
pulsa
tility 
index 
(HA
PI) 
PV 
cs 
area 
 
Spleen 
size 
cm 
SAR
I 
Liver 
vasc
ular 
index 
Conge
stive 
index 
PHT 
index 
           
           
           
  
 
 
                       
 
 
 
 
 
 
 
